



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/164684/>

Version: Accepted Version

Article:

Cooper, K., Tappenden, P., Cantrell, A. et al. (2020) A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. *British Journal of Cancer*, 123 (11). pp. 1686-1696. ISSN: 0007-0920

<https://doi.org/10.1038/s41416-020-01050-w>

This is a post-peer-review, pre-copyedit version of an article published in *British Journal of Cancer*. The final authenticated version is available online at:

<https://doi.org/10.1038/s41416-020-01050-w>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

1 **A systematic review of meta-analyses assessing the validity of tumour response**
2 **endpoints as surrogates for progression-free or overall survival in cancer**

3

4 **Running title: Systematic review of response as surrogate for survival**

5

6 **List of authors:**

7 *Katy Cooper, Senior Research Fellow, ScHARR, University of Sheffield,

8 k.l.cooper@sheffield.ac.uk, ORCID 0000-0002-7702-8103

9 Paul Tappenden, Professor of Health Economic Modelling, ScHARR, University of Sheffield

10 Anna Cantrell, Information Specialist, ScHARR, University of Sheffield

11 Kate Ennis, Research Associate, ScHARR, University of Sheffield

12 *corresponding author

13

14 25 February 2020

15

16 **Competing interests**

17 The authors have no competing interests.

18

19

20 **Abstract**

21 **Background:** Tumour response endpoints, such as overall response rate (ORR) and complete response
22 (CR), are increasingly used in cancer trials. However, the validity of response-based surrogates is
23 unclear. This systematic review summarises meta-analyses assessing the association between response-
24 based outcomes and overall survival (OS), progression-free survival (PFS) or time-to-progression
25 (TTP).

26 **Methods:** Five databases were searched to March 2019. Meta-analyses reporting correlation or
27 regression between response-based outcomes and OS, PFS or TTP were summarised.

28 **Results:** The systematic review included 63 studies across 20 cancer types, most commonly non-small
29 cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer. The strength of association
30 between ORR or CR and either PFS or OS varied widely between and within studies, with no clear
31 pattern by cancer type. The association between ORR and OS appeared weaker and more variable than
32 that between ORR and PFS, both for associations between absolute endpoints and associations between
33 treatment effects.

34 **Conclusions:** This systematic review suggests that response-based endpoints such as ORR and CR may
35 not be reliable surrogates for PFS or OS. Where it is necessary to use tumour response to predict
36 treatment effects on survival outcomes, it is important to fully reflect all statistical uncertainty in the
37 surrogate relationship.

38

39 **Introduction**

40 Decisions about the use of new and existing health technologies should ideally be informed by estimates
41 of treatment effects derived from high quality randomised controlled trials (RCTs) which measure
42 patient-relevant endpoints over a clinically appropriate timeframe. Such “final” endpoints typically
43 involve the measurement of health benefits which reflect aspects of the disease and its treatment which
44 are important to patients (and potentially also their carers) and which relate to “how the patient feels,
45 functions or survives.”¹ In the context of advanced/metastatic cancer, the key matter of concern is often
46 whether the use of a given health technology leads to improvements in overall survival (OS; a final
47 endpoint) compared to existing standard treatments. However, the estimation of treatment effects on
48 OS may be subject to numerous problems, including: potential confounding resulting from the use of
49 post-progression treatments, insufficient study follow-up resulting in data immaturity, or simply that
50 data on OS have not been collected. In such instances, determining the impact of health technologies
51 becomes more challenging and may rely on the use of surrogate endpoints to substitute for, and predict,
52 a final patient-relevant clinical outcome.² Potentially relevant surrogate endpoints vary according to
53 tumour type and site, but commonly include progression-free survival (PFS), time to progression (TTP),
54 and response-based outcomes, which may include overall response rate (ORR), different levels of
55 response (e.g. complete response [CR], partial response [PR] or very good partial response [VGPR])
56 and duration of response (DoR). These surrogate endpoints are often considered attractive as they
57 typically require smaller sample sizes, occur faster and are less expensive to collect in clinical trials
58 compared with final outcomes, thereby reducing costs associated with data collection and expediting
59 the time required for bringing new technologies to market.

60 It has been recognised in the literature that the reliance on surrogates may lead to invalid conclusions
61 regarding the net health effects of technologies, which in turn, have the potential to lead to patient
62 harm.³ Much of the published literature around the use of surrogate endpoints has focussed on the
63 development and application of frameworks for their validation.^{4,5} In his seminal paper, Prentice⁴ put
64 forward stringent criteria for the validation of surrogate endpoints in Phase III trials. In general terms,
65 these criteria require that the surrogate endpoint must be a correlate of the net effect of treatment on the

66 final clinical outcome – in other words, there must be a single pathway from the treatment to the true
67 endpoint which is mediated exclusively by the surrogate endpoint.⁶ Applied surrogate validation studies
68 commonly adopt a meta-analytic (meta-regression) approach based on multiple studies in order to
69 assess whether the apparent relationship between the surrogate and the final endpoint remains constant
70 in the presence of various sources of heterogeneity, such as differences in patient population, study
71 design and treatments received.⁵

72 Based on the NIH Biomarkers Definition Working Group's preferred terms and definitions⁷ and the
73 2001 Journal of the American Medical Association (JAMA) User's Guide,⁸ Taylor and Elston⁹
74 proposed a hierarchy of levels of surrogate validation. Level 3 of the hierarchy relates to biological
75 plausibility – this is the weakest form of validation and is typically based on pathophysiological studies
76 and/or an understanding of the disease process. Level 2 requires the presence of a consistent association
77 between the surrogate outcome and the final endpoint; this may be assessed using observational studies
78 or arm-based analyses of trials which have measured both the surrogate and the final outcome. This
79 level of validation requires an assessment of the individual-level (absolute) association between
80 endpoints, and is usually undertaken using correlation analysis. Level 1 of the hierarchy represents the
81 strongest level of surrogate validation: in order to achieve this level of validation, the treatment effect
82 on the surrogate must correspond to the treatment effect on the final outcome. Demonstrating this level
83 of validity requires an analysis of correlation in terms of treatment effects between arms based on data
84 from RCTs (trial-level association). Other validation frameworks have been proposed to assess the
85 strength of association between surrogate and final endpoints. These include the criteria proposed by
86 the German Institute of Quality and Efficiency in Health Care¹⁰ (IQWiG; based on the treatment effect
87 association only) and the Biomarker-Surrogate Evaluation Schema criteria¹¹ (BSES2; based on both
88 absolute and treatment effect associations). These frameworks differ in terms of the types of analyses
89 and the strength of the relationship required to determine the reliability of the surrogate.

90 This systematic review summarises published meta-regression studies reporting correlation and
91 regression analyses for the strength of the association between response-based outcomes and PFS, TTP

92 or OS in (primarily) advanced or metastatic cancer, across any tumour site, in order to assess whether
93 response-based outcomes may be considered as valid surrogates for PFS, TTP or OS.

94

95 **Methods**

96 **Inclusion and exclusion criteria**

97 Inclusion was restricted to articles reporting meta-analyses or meta-regressions across multiple studies,
98 and reporting the strength of association between response outcomes (ORR, CR, PR, VGPR or DoR)
99 and either PFS, TTP or OS. The included meta-regressions could themselves include RCTs and/or
100 single-arm studies. However, individual reports analysing single trials or single cohorts were excluded
101 from this review. Included meta-analyses could report absolute associations and/or treatment effect
102 associations. These associations had to be reported as a correlation coefficient (e.g. Pearson r or
103 Spearman r_s) and/or a coefficient of determination (R^2) between relevant outcomes.

104 Studies of any cancer and any treatment were included. The review focussed mainly on studies of
105 advanced or metastatic cancers (and/or treatment with palliative intent), as these studies were more
106 likely to report PFS and OS. However, studies reporting relevant outcomes were included even where
107 the stage was not specifically restricted to advanced/metastatic disease for all patients or where this was
108 unclear (this applied particularly to haematological cancers). Studies were excluded if they explicitly
109 referred to adjuvant or neo-adjuvant treatment, or treatments which are given with curative intent.
110 Studies were only included if they were written on English or contained sufficient detail in English.

111 The review protocol is registered on PROSPERO with registration number CRD42019127606.

112 **Search strategy**

113 Five databases (MEDLINE, EMBASE, Web of Science, the Cochrane Database of Systematic Reviews
114 and CINAHL) were searched from inception to March 2019. Search terms included: cancer terms AND
115 response terms AND terms for PFS, TTP and/or OS AND terms for regression, correlation, prediction,

116 association or relationship AND terms for endpoint and/or surrogate. Search results were limited to the
117 English language and to studies undertaken in humans. The MEDLINE search strategy is provided in
118 Supplementary Information 1. In addition, a citation search was undertaken based on two existing meta-
119 reviews of surrogate relationships; this identified studies which have cited any of the 48 articles included
120 in the review by Fischer *et al.* (2016)¹² and/or any of the 19 articles included in the review by Davis *et al.*
121 *al.* (2012).¹³ In addition, relevant existing meta-reviews, including Fischer *et al.* (2016),¹² Davis *et al.*
122 (2012),¹³ Savina *et al.* (2018),¹⁴ Haslam *et al.* (2019)¹⁵ and any reviews identified during searching,
123 were checked for relevant studies.

124 **Scoring the strength of association: IQWiG and BSES2 scoring**

125 In this review, two sets of published criteria were used to assess the strength of association between
126 surrogate and final endpoints: the IQWiG criteria¹⁰ and the BSES2 criteria.¹¹

127 The IQWiG criteria¹⁰ are based on the correlation coefficient (r) for the treatment effect association.
128 Where r was not reported, it was calculated as the square-root of R^2 , if available. As the Medium score
129 bracket was not clearly defined, slight modifications were made to the IQWiG criteria based on the
130 approach used in the previous review by Savina *et al.*¹⁴ (Supplementary Table 1). The IQWiG score
131 was generated based on the magnitude of r , irrespective of its sign (i.e. a negative correlation could
132 generate a high score). The IQWiG criteria were scored as follows: High (lower confidence interval of
133 r is ≥ 0.85); Medium+ ($r \geq 0.85$ with no reported confidence interval or $r \geq 0.85$ with wide confidence
134 intervals [lower limit < 0.85]); Medium ($0.85 > r \geq 0.7$ and upper confidence interval of r is ≥ 0.7 and
135 lower confidence interval of r is < 0.85 , or $0.85 > r \geq 0.7$ with no reported confidence interval); or Low
136 (upper confidence interval of r is < 0.7 or $r < 0.7$ with no reported confidence interval).

137 The BSES2 criteria¹¹ require R^2 values for both the absolute and treatment effect associations. Where
138 R^2 was not reported, it was calculated as the square of r , if available. BSES2 criteria were used as an
139 adaptation from the original BSES criteria, as described in Savina *et al.* (2018).¹⁴ The original BSES
140 criteria require R^2 for both individual and treatment effect associations and a value for the surrogate
141 threshold effect (STE). Since so few articles report STE, this review used BSES2, which does not

142 require the STE. The BSES2 criteria were scored as follows: Excellent (R^2 [treatment effect] ≥ 0.6 and
143 R^2 [absolute] ≥ 0.6); Good (R^2 [treatment effect] ≥ 0.4 and R^2 [absolute] ≥ 0.4); Fair (R^2 [treatment
144 effect] ≥ 0.2 and R^2 [absolute] ≥ 0.2); Poor (R^2 [treatment effect] < 0.2 and/or R^2 [absolute] < 0.2).
145 Further details on the IQWiG and BSES2 scoring systems are provided in Supplementary Tables 1 and
146 2.

147

148 **Study selection and data extraction**

149 Titles and abstracts of articles retrieved by the search were examined by one reviewer and a subset were
150 checked by a second reviewer early in the process, followed by a discussion to ensure consistency in
151 the selection decisions. Full texts were examined by one reviewer and a subset were checked by a
152 second reviewer, with any discrepancies resolved through discussion.

153 Data were extracted by one reviewer and all data were checked by a second reviewer. Data were
154 extracted relating to study design, participant characteristics, surrogate and final endpoints analysed,
155 methods for correlation and regression, and results including absolute associations, associations
156 between treatment effects, STE and regression equations.

157 **Data synthesis**

158 Data were presented in a narrative synthesis. Plots were constructed to illustrate the reported
159 associations within each study. Some of the included meta-regression studies reported multiple
160 subgroup analyses with differing results. Therefore, each horizontal row in the plots illustrates the range
161 of reported associations across all subgroup analyses within a single meta-regression study. Where an
162 included meta-regression study reported on more than one cancer type, these are shown on separate
163 rows on the plots.

164 For associations between absolute values of endpoints, the plots show the range of correlation
165 coefficients per study, across all subgroup analyses. All types of correlation coefficient were included,

166 e.g. Pearson r and Spearman r_s. If no correlation coefficient was reported, then Pearson r was calculated
167 as the square-root of R², if available.

168 For associations between treatment effects, the plots show the range of regression coefficients of
169 determination (R²) per study, across all subgroup analyses. The plots include both adjusted and
170 unadjusted R² values, as well as values from weighted and unweighted regressions. For studies in which
171 R² was not reported, this was calculated as the square of the Pearson r correlation coefficient, if
172 available. R² was not calculated from other correlation coefficients such as Spearman, or where the
173 method of correlation was unclear.

174 **Quality assessment**

175 Included meta-regression studies were assessed for methodological quality based on key criteria from
176 the AMSTAR-2¹⁶ and ReSEEM¹⁷ checklists most relevant to our review.

177 **Results**

178 **Number of included meta-regression studies**

179 The literature search generated 2,829 citations (Figure 1), of which 2,630 were excluded during the
180 review of titles and abstracts and a further 135 excluded during the review of full texts. In total, 63
181 studies (within 64 references) were included in the review.¹⁸⁻⁸¹

182 **Characteristics of included meta-regression studies**

183 Summaries of study characteristics and reported data types are provided in Supplementary Tables 3 and
184 4 respectively, while full details of study characteristics for each of the 63 included studies are provided
185 in Supplementary Table 5.

186 The most commonly reported surrogate relationships were ORR to OS (57 studies), ORR to PFS (22
187 studies), CR to OS (8 studies) and CR to PFS (7 studies). Other response outcomes (DoR, PR,
188 VGPR/CR) were only reported in 1-2 studies each. Twenty different cancer types were analysed, the
189 most common being NSCLC (16 studies), CRC (10 studies), various solid tumours (8 studies) and

190 breast cancer (5 studies). Disease stage was advanced/metastatic in 43 studies and unclear in 9 studies,
191 while the remainder (11 studies) gave other descriptions mostly indicating advanced, extensive or
192 recurrent disease. Treatment was first-line in 23 studies, later lines or combinations of lines in 32
193 studies, and not reported in 8 studies. Treatment type was chemotherapy in 21 studies, immune
194 checkpoint inhibitors in 9 studies, targeted therapy in 8 studies, and various other treatment
195 combinations in the remainder.

196 The various meta-regressions included between 4 and 191 primary studies and between 407 and 44,125
197 patients each. The majority of meta-regressions (N=44) included only RCTs, while 17 included both
198 RCTs and single-arm studies and 2 included only single-arm studies. Most meta-regressions (N=58)
199 analysed aggregate data (e.g. medians or other summary measures per study arm), whilst 5 analysed
200 individual patient data (IPD). Across all meta-regressions, 32 reported absolute (individual-level)
201 associations, 38 reported treatment effect (trial-level) associations, and only 4 reported the STE.

202

203 **Methodological quality of included meta-regression studies**

204 Methodological quality of the included studies is shown in Supplementary Table 6. All studies had clear
205 inclusion criteria; 65% reported a comprehensive literature search; and 98% reported a correlation
206 coefficient or R^2 value (the one study not reporting these was included as it reported a regression slope).
207 However, only 27% reported duplicate study selection; 48% reported duplicate data extraction or
208 checking; and 13% reported a risk of bias assessment of included studies. In addition, only 37%
209 explored heterogeneity through subgroup analyses, and only 40% reported confidence intervals around
210 the correlation coefficient or R^2 .

211

212 **Results of included studies**

213 The reported associations between surrogate and final endpoints are summarised in Table 1 and
214 illustrated in Figure 2 to Figure 5. Full results for each included meta-regression study are provided in
215 Supplementary Table 7 (for absolute associations) and Supplementary Table 8 (for treatment effect
216 associations).

217 **Absolute (individual-level) correlation and regression**

218 The range of absolute (individual-level) correlation coefficients is summarised in Table 1 and illustrated
219 in Figure 2 (for the association between ORR and PFS) and Figure 3 (for the association between ORR
220 and OS). Some of the included meta-regression studies reported multiple subgroup analyses with
221 differing results. Therefore, each horizontal row in the plots illustrates the range of correlation
222 coefficients across all subgroup analyses within a single meta-regression study. Where an included
223 meta-regression reported on more than one cancer type, these are shown on separate rows on the plots.
224 It is worth noting that the included meta-regression studies differed in terms of various factors, such as
225 the number of included primary studies (shown as N on the plots), treatment type, line of treatment and
226 precise clinical population (full details in Supplementary Table 7).

227 **ORR and PFS (or TTP):** The reported correlation coefficients (Pearson r or Spearman r_s) between
228 absolute ORR and PFS ranged from -0.72 to 0.96, based on multiple analyses within 12 studies across
229 10 cancer types^{44,45,52,54,55,59,62,63,65,66,72,78} (Figure 2 and Table 1). Across those studies which report only
230 a single analysis, the correlation coefficient was generally above 0.60; however, some estimates were
231 lower. Confidence intervals around the correlation coefficients were rarely reported. Few separate meta-
232 regressions reported on the same tumour site, hence it is difficult to assess whether ORR may be a more
233 reliable surrogate in certain cancer types than others. One study reported on ORR and TTP (gastric
234 cancer; correlation $r_s = 0.41$ to 0.56 across subgroup analyses, not shown on the plot).⁴²

235 **ORR and OS:** The reported correlation coefficients between absolute ORR and OS ranged from -0.40
236 to 1.00, based on 27 studies across 15 cancer types^{18,43,19,20,35,37,38,42,45,49-52,59-66,68,70-72,75,78} (Figure 3 and
237 Table 1). Confidence intervals around the correlation coefficients, where reported, were generally fairly

238 wide. The majority of correlation coefficients were above 0.40; however, several estimates were lower.
239 Neither the correlation coefficients reported from multiple analyses within the same study, nor those
240 reported across separate studies, suggested a clear pattern by cancer type.

241 **CR and PFS or OS:** The correlation coefficients between absolute CR and PFS in two studies of small-
242 cell lung cancer (SCLC)⁵⁹ and non-Hodgkin's lymphoma (NHL)⁸¹ ranged from 0.22 to 0.83, while the
243 correlation coefficients between absolute CR and OS ranged from -0.04 to 0.62, based on 3 studies of
244 NSCLC,⁴⁹ SCLC⁵⁹ and gastroesophageal cancer⁶¹ (Table 1).

245 **PR and PFS or OS:** The correlation coefficient between absolute PR and PFS ranged from 0.35 to 0.70
246 across subgroup analyses within one study of SCLC,⁵⁹ while the highest correlation coefficient between
247 absolute PR and OS ranged from 0.29 to 0.66 in the same study⁵⁹ (Table 1).

248 **DoR and PFS or OS:** No studies reported on the absolute association between DoR and PFS or OS.

249 **Treatment effect (trial-level) correlation and regression**

250 The range of treatment effect (trial-level) R^2 values is summarised in Table 1 and illustrated in Figure
251 4 (for the association between ORR and PFS) and Figure 5 (for the association between ORR
252 and OS). Each horizontal row in the plots illustrates the range of R^2 values across all subgroup analyses
253 within a single meta-regression study. Where an included meta-regression reported on more than one
254 cancer type, these are shown separately on the plots. It is worth noting that the meta-regressions differed
255 in terms of the number of included primary studies (shown as N on the plots), treatment type, line of
256 treatment and precise clinical population (full details in Supplementary Table 8).

257 **ORR and PFS:** The regression R^2 values for the treatment effect association between ORR and PFS
258 ranged from 0.18 to 0.94, based on 9 studies across 4 cancer types: NSCLC,^{21,22,45,67,77} ovarian
259 cancer,^{27,72} colorectal cancer^{26,77} and various solid tumours^{67,77,79} (Figure 4 and Table 1). The majority
260 of R^2 values were above 0.40. The R^2 values reported from multiple analyses within the same study,
261 and those reported across separate studies, did not suggest a clear pattern by cancer type. Confidence
262 intervals around the R^2 values, where reported, were generally fairly wide.

263 **ORR and OS:** The regression R^2 values for the treatment effect association between ORR and OS
264 ranged from -0.08 to 0.84, based on 31 studies across 11 cancer types^{21-23,25-32,34,36,37,39-41,45-47,53,56-}
265 ^{58,60,63,67,73,74,77,79} (Figure 5 and Table 1). With the exception of one analysis,⁷⁷ all R^2 values were below
266 0.60. The R^2 values reported from multiple analyses within the same study, and those reported across
267 separate studies, did not suggest a clear pattern by cancer type. Confidence intervals around the R^2
268 values, where reported, were generally wide.

269 **CR and PFS or OS:** The regression R^2 for the treatment effect association between CR and PFS ranged
270 from 0.45 to 0.93 across subgroup analyses within one study of NHL,⁶⁹ while the regression R^2 for the
271 treatment effect association between CR and OS within two studies of breast cancer³⁶ and SCLC³⁴
272 ranged from 0.05 to 0.48 (Table 1).

273 **PR and PFS or OS:** No studies reported the treatment effect association between PR and PFS or OS.

274 **DoR and PFS or OS:** No studies reported R^2 between DoR and OS or PFS. Two studies in colorectal
275 cancer²⁹ and pancreatic cancer²⁸ reported Spearman correlation coefficients between DoR and OS
276 ranging from 0.40 to 0.76 (Table 1).

277

278 **Influence of clinical and study factors on association**

279 The impact of the following patient and study factors on the association between ORR and OS was
280 explored: treatment line; treatment type; response criteria; adjustment of OS for crossover and post-
281 progression treatments; and aggregate versus IPD data (Supplementary Table 9). No clear effect on the
282 association between ORR and OS was identified for any individual factor. However, this analysis was
283 limited by the small number of publications assessing each factor within each cancer, and the wide
284 ranges of associations observed for each.

285 Five of the 63 included meta-analyses analysed IPD rather than aggregate data; two in breast cancer
286 (Bruzzi 2005²³ Burzykowski 2008²⁴), one in colorectal cancer (Buyse 2000²⁵), one in NHL (Shi 2017⁶⁹)
287 and one in ovarian cancer (Rose 2010⁶⁶). The associations reported in these studies were not noticeably
288 different to those in other studies (see Figures 2 to 5).

289

290 **Regression equations**

291 Regression equations were reported in fourteen studies for the relationship between ORR and OS; of
292 these, four reported absolute associations^{42,52,72,76} and ten reported treatment effect associations.<sup>31-
293 33,36,41,46,56,58,67,77</sup> Regression equations were also reported in eight studies for the relationship between
294 ORR and PFS; of these, four reported absolute associations^{52,54,72,76} and four reported treatment effect
295 associations.^{24,33,67,77} These analyses spanned 10 cancer types. Full details are provided in
296 Supplementary Tables 10 and 11. There was substantial variation in the effect measures used for both
297 the surrogate and final outcomes; for example, difference in medians, hazard ratio (HR), odds ratio
298 (OR), log-transformed or not. None of the included studies attempted to externally validate their
299 regression equations for the relationship between response and other outcomes.

300 **Surrogate threshold effect (STE)**

301 The STE - the smallest treatment effect on the surrogate that predicts a non-zero treatment effect on the
302 true endpoint⁸² - was reported in only four studies (Supplementary Table 12).^{26,39,69,77} For the
303 relationship between ORR and PFS, one study⁷⁷ in various solid tumours reported that a difference in
304 ORR of 15% would be required to predict a non-zero treatment effect on the HR for PFS. For the
305 relationship between ORR and OS, two studies in various solid tumours⁷⁷ and NSCLC³⁹ reported that a
306 difference in ORR of 21% and 55% respectively would be required to predict a non-zero treatment
307 effect on the HR for OS, while one study³⁹ also reported that a difference in ORR of 41% would be
308 required to predict a non-zero treatment effect on the difference in median OS. A further study in
309 colorectal cancer²⁶ reported that an OR for ORR of 0.28 would be required to predict a non-zero
310 treatment effect on the OR for OS. Finally, for the relationship between CR and PFS, one study in
311 NHL⁶⁹ reported that an OR for CR (at 30 months) of 1.56 would be required to predict a non-zero
312 treatment effect on the HR for PFS.

313 **IQWiG and BSES2 scores for strength of association**

314 IQWiG and BSES2 scores for the strength of association between surrogate and final endpoints were
315 calculated for all reported subgroup analyses with sufficient data; therefore, meta-regression studies
316 that reported more subgroups are more strongly represented in this analysis. These data are presented
317 graphically in Supplementary Figures 1 and 2.

318 In terms of IQWiG scores, of 202 analyses (across 63 studies), 0 (0%) scored high, 15 (7%) scored
319 medium+, 26 (13%) scored medium, 76 (38%) scored low and 85 (42%) were not evaluable. In terms
320 of BSES2 scores, of 202 analyses (across 63 studies), 0 (0%) scored excellent, 3 (1%) scored good, 3
321 (1%) scored fair, 7 (3%) scored poor and 189 (94%) were not evaluable.

322

323 **Discussion**

324 This systematic review summarises published meta-regression studies reporting correlation and
325 regression analyses for the strength of the association between response outcomes and PFS, TTP or OS
326 across different types of cancer. In total, the review included 63 studies across 20 cancer types. The
327 most commonly analysed relationships were between ORR and either PFS or OS.

328 For the association between ORR and PFS, the majority of reported correlation coefficients between
329 absolute values were above 0.60 (range -0.72 to 0.96). For association between treatment effects on
330 ORR and PFS, the majority of regression R^2 values were above 0.40 (range 0.18 to 0.94). The
331 association between ORR and OS appeared weaker than that between ORR and PFS; while the majority
332 of reported correlation coefficients between absolute values were above 0.40, several estimates were
333 lower (range -0.40 to 1.00). For association between treatment effects on ORR and OS, all regression
334 R^2 values except one were below 0.60 (range -0.08 to 0.84).

335 There was no clear pattern by cancer type for either the absolute or treatment effect associations, based
336 on both multiple analyses within the same study and results across separate studies. Confidence

337 intervals around the reported correlation coefficients and R^2 values were generally wide and often not
338 reported.

339 Strength of association across all subgroup analyses within all included meta-regression studies was
340 assessed using the IQWiG and BSES2 scoring systems. The majority of analyses were not evaluable
341 due to lack of required data. Of those analyses that could be scored, scores were relatively low,
342 suggesting that response-based endpoints may be poor surrogates for OS.

343 Previous systematic reviews of surrogate endpoints in advanced cancer have been published. Savina *et*
344 *al* and Haslam *et al* have reported systematic reviews of meta-analyses assessing any endpoint as a
345 surrogate for OS.^{14,15} Both of these reviews also assessed the strength of association using surrogate
346 validation frameworks; both studies used adaptations of the IQWiG framework, and Savina *et al* also
347 used the BSES2 framework. These previous reviews generally focussed on the main analyses presented
348 within individual meta-analyses (usually that with the largest number of patients). Similar to our review,
349 these previous reviews suggested that response-based outcomes are likely to be poor surrogates for OS.
350 Our systematic review focusses exclusively on response-based surrogates; it includes a comprehensive
351 search to identify relevant studies, considers PFS as a potential final endpoint as well as OS, is more up
352 to date, includes a greater number of studies, and reports results for the full breadth of analyses reported
353 in the included meta-regression studies compared with these previous reviews. This provides a more
354 complete picture of the extent of heterogeneity in reported relationships across the full range of meta-
355 analyses across each cancer area. This additional breadth provides a better basis to inform judgements
356 about the validity of response-based endpoints as a surrogate for PFS or OS.

357 The review is subject to a number of limitations. The reported data were highly heterogeneous in terms
358 of effect measure and method of analysis. Therefore, some simplifying assumptions had to be made to
359 allow the data to be summarised. For example, correlation coefficients were summarised regardless of
360 method (Pearson, Spearman or other); R^2 values were summarised irrespective of whether or not the
361 regression was weighted and whether or not the R^2 was adjusted; and for treatment effect associations,
362 R^2 values were summarised regardless of the effect measure (e.g. HR, OR, difference in medians). In

363 addition, only five studies used IPD rather than aggregate data in their analysis; this is a limitation of
364 the analyses conducted in the majority of meta-reviews. A recent review by Xie *et al* highlighted wide
365 variability in reporting standards across surrogate evaluation meta-regression studies; future analyses
366 should attempt to adhere to current best practice, for example, the reporting of surrogate endpoint
367 evaluation using meta-analyses (ReSEEM) guidelines in order to improve the quality of these
368 analyses.¹⁷

369 It should further be noted that whilst meta-regression has been widely used for the purpose of evaluating
370 the validity of surrogate endpoints in oncology, this method has been criticised as it ignores uncertainty
371 around the treatment effect on the surrogate outcome (which is treated as a fixed covariate in the
372 analysis). Newer methods, such as the bivariate random effects meta-analysis (BRMA) model reported
373 by Bujkiewicz *et al*,⁸³ provides an approach for both the validation and prediction of surrogate endpoints
374 within a Bayesian framework. This approach allows for borrowing of information across studies and
375 fully accounts for all uncertainty surrounding the surrogate relationship. In spite of the generally poor
376 association between response-based outcomes and final outcomes, there may still be instances in which
377 generating predictions on the basis of response is necessary; for example, within health economic
378 models, or more broadly, for decision-making within health technology assessment. In instances where
379 the surrogate association is weak, this uncertainty would manifest as a wider prediction interval. If such
380 predictions are necessary, it is therefore important that all uncertainty is reflected in the model. Future
381 surrogate evaluation studies should consider the use of the BRMA model, rather than conventional
382 meta-regression, as a means of fully reflecting this uncertainty.

383

384 **Conclusions**

385 This systematic review suggests that response-based endpoints such as ORR and CR may not be reliable
386 surrogates for PFS or OS in cancer treatment. Strength of association varied widely between and within
387 studies, with no clear pattern by cancer type. The strength of association between ORR and OS appeared
388 weaker and more variable than that between ORR and PFS, both for associations between absolute

389 endpoints and associations between treatment effects. Whilst there may still be value in using response
390 outcomes as a means of predicting final outcomes such as OS, it is important that those predictions are
391 made on the basis of models which fully reflect the uncertainty around the treatment effect on the
392 surrogate outcome.

393

394 **Additional Information**

395 **Acknowledgements**

396 Thanks to Andrea Shippam for administrative and Endnote support.

397 **Authors' contributions**

398 KC and PT designed the protocol, selected studies, and extracted and analysed data. AC designed and
399 undertook the literature searches. KE selected studies and extracted data. All authors inputted to the
400 manuscript.

401 **Ethics approval and consent to participate**

402 Ethics approval was not required since all data were already in the public domain.

403 **Consent for publication**

404 Consent for publication was not required since all data were already in the public domain.

405 **Data availability**

406 All data are provided in the tables, figures and supplementary information.

407 **Conflict of interest**

408 The authors declare no conflicts of interest.

409 **Funding**

410 This study was funded by the UK National Institute for Health Research (NIHR) Health Technology
411 Assessment (HTA) Programme, project number NIHR127852.

413 **References**

- 414 1. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. *Statistics in*
415 *Medicine*; **31**(25), 2973-2984 (2012).
- 416 2. Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness
417 analyses: a survey of UK Health Technology Assessment reports. *Health Technology*
418 *Assessment*; **13**(8), 1-72 (2009).
- 419 3. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? *Annals*
420 *of Internal Medicine*; **125**(7), 605-613 (1996).
- 421 4. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria.
422 *Statistics in Medicine*; **8**(4), 431-440 (1989).
- 423 5. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate
424 endpoints in meta-analyses of randomized experiments. *Biostatistics*; **1**(1), 49-67 (2000).
- 425 6. Heller G. Statistical controversies in clinical research: an initial evaluation of a surrogate end
426 point using a single randomized clinical trial and the Prentice criteria. *Annals of Oncology*;
427 **26**(10), 2012-2016 (2015).
- 428 7. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred
429 definitions and conceptual framework. *Clinical Pharmacology & Therapeutics*; **69**(3), 89-95
430 (2001).
- 431 8. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical
432 literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect
433 of an intervention on surrogate end points. *JAMA*; **282**(8), 771-778 (1999).
- 434 9. Elston J, Taylor RS. Use of surrogate outcomes in cost-effectiveness models: a review of
435 United Kingdom health technology assessment reports. *Int J Technol Assess Health Care*;
436 **25**(1), 6-13 (2009).
- 437 10. German Institute of Quality and Efficiency in Health Care (IQWiG). Validity of surrogate
438 endpoints in oncology. (2011).
- 439 11. Lassere MN, Johnson KR, Schiff M, Rees D. Is blood pressure reduction a valid surrogate
440 endpoint for stroke prevention? An analysis incorporating a systematic review of randomised
441 controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold
442 effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES). *BMC*
443 *Med Res Methodol*; **12**, 27 (2012).
- 444 12. Fischer A, Hernandez-Villafuerte K, Latimer N, Henshall C. Extrapolation from Progression-
445 Free Survival to Overall Survival in Oncology. Office of Health Economics;(2016).
- 446 13. Davis S, Tappenden P, Cantrell A. A review of studies examining the relationship between
447 progression-free survival and overall survival in advanced or metastatic cancer. University of
448 Sheffield report for NICE Decision Support Unit (2012).
- 449 14. Savina M, Gourgou S, Italiano A, Dinart D, Rondeau V, Penel N *et al.* Meta-analyses
450 evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical
451 review. *Critical Reviews in Oncology Hematology*; **123**, 21-41 (2018).
- 452 15. Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses
453 measuring the strength of association between surrogate end-points and overall survival in
454 oncology. *European Journal of Cancer*; **106**, 196-211 (2019).

- 455 16. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J *et al.* AMSTAR 2: a critical
456 appraisal tool for systematic reviews that include randomised or non-randomised studies of
457 healthcare interventions, or both. *BMJ*; **358**, j4008 (2017).
- 458 17. Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ *et al.* A Systematic Review
459 and Recommendation for Reporting of Surrogate Endpoint Evaluation using Meta-analyses
460 (ReSEEM). *JNCI Cancer Spectrum* (2019).
- 461 18. Abdel-Rahman O. Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for
462 urinary cancers: a systematic review. *Immunotherapy*; **10**(2), 139-148 (2018).
- 463 19. Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ *et al.* Six-month
464 progression-free survival as the primary endpoint to evaluate the activity of new agents as
465 second-line therapy for advanced urothelial carcinoma. *Clinical Genitourinary Cancer*; **12**(2),
466 130-137 (2014).
- 467 20. Agarwal SK, Mangal N, Menon RM, Freise KJ, Salem AH. Response Rates as Predictors of
468 Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. *J Cancer*; **8**(9), 1562-
469 1567 (2017).
- 470 21. Blumenthal GM, Karuri SW, Zhang H, Zhang LJ, Khozin S, Kazandjian D *et al.* Overall
471 Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard
472 Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration
473 Trial-Level and Patient-Level Analyses. *Journal of Clinical Oncology*; **33**(9), 1008 (2015).
- 474 22. Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S *et al.* Milestone
475 Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in
476 Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. *JAMA Oncology*; **3**(8),
477 e171029 (2017).
- 478 23. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C *et al.* Objective
479 response to chemotherapy as a potential surrogate end point of survival in metastatic breast
480 cancer patients. *Journal of Clinical Oncology*; **23**(22), 5117-5125 (2005).
- 481 24. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ *et al.*
482 Evaluation of tumor response, disease control, progression-free survival, and time to
483 progression as potential surrogate end points in metastatic breast cancer. *Journal of Clinical
484 Oncology*; **26**(12), 1987-1992 (2008).
- 485 25. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation
486 between tumour response to first-line chemotherapy and survival in advanced colorectal
487 cancer: A meta-analysis. *Lancet*; **356**(9227), 373-378 (2000).
- 488 26. Ciani O, Buyse M, Garside R, Peters J, Saad ED, Stein K *et al.* Meta-analyses of randomized
489 controlled trials show suboptimal validity of surrogate outcomes for overall survival in
490 advanced colorectal cancer. *Journal of Clinical Epidemiology*; **68**(7), 833-842 (2015).
- 491 27. Colloca G, Venturino A. Trial-level analysis of progression-free survival and response rate as
492 end points of trials of first-line chemotherapy in advanced ovarian cancer. *Medical Oncology*;
493 **34**(5), 87 (2017).
- 494 28. Colloca G, Venturino A, Guarneri D. Analysis of Response-Related and Time-to-event
495 Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone
496 as First-Line Treatment of Patients With Advanced Pancreatic Cancer. *Clinical Colorectal
497 Cancer*; **15**(3), 264-276 (2016a).
- 498 29. Colloca G, Venturino A, Guarneri D. Analysis of Clinical End Points of Randomised Trials
499 Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of
500 Metastatic Colorectal Cancer. *Clinical Oncology (Royal College of Radiologists)*; **28**(10),
501 e155-164 (2016b).

- 502 30. Colloca G, Vitucci P, Venturino A. Trial Level Analysis of Prostate-Specific Antigen-Related
503 Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical
504 Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer. *Clinical*
505 *Genitourinary Cancer*; **14**(5), 389-397 (2016c).
- 506 31. Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Barattelli C *et al.*
507 Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal
508 Cancer: A Literature-Based Systematic Review and Meta-Analysis. *Cancer Research &*
509 *Treatment*; **49**(3), 834-845 (2017).
- 510 32. Delea TE, Khuu A, Heng DYC, Haas T, Soulieres D. Association between treatment effects
511 on disease progression end points and overall survival in clinical studies of patients with
512 metastatic renal cell carcinoma. *British Journal of Cancer*; **107**(7), 1059-1068 (2012).
- 513 33. Elia EG, Städler N, Ciani O, Taylor RS, Bujkiewicz S. Combining tumour response and
514 progression free survival as surrogate endpoints for overall survival in advanced colorectal
515 cancer. *arXiv preprint arXiv:180902935* (2018).
- 516 34. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR *et al.* Tumor response and progression-
517 free survival as potential surrogate endpoints for overall survival in extensive stage small-cell
518 lung cancer: findings on the basis of North Central Cancer Treatment Group trials. *Cancer*;
519 **117**(6), 1262-1271 (2011).
- 520 35. Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Schulz C *et al.* Surrogate
521 endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23
522 randomised trials. *Acta Oncologica*; **54**(2), 187-193 (2015).
- 523 36. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women
524 receiving first-line combination anthracycline chemotherapy for advanced breast cancer.
525 *British Journal of Cancer*; **93**(11), 1215-1221 (2005).
- 526 37. Hamada T, Nakai Y, Isayama H, Yasunaga H, Matsui H, Takahara N *et al.* Progression-free
527 survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic
528 cancer. *European Journal of Cancer*; **65**, 11-20 (2016).
- 529 38. Han K, Ren M, Wick W, Abrey L, Das A, Jin J *et al.* Progression-free survival as a surrogate
530 endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
531 *Neuro-Oncology*; **16**(5), 696-706 (2014).
- 532 39. Hashim M, Pfeiffer BM, Bartsch R, Postma M, Heeg B. Do Surrogate Endpoints Better
533 Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported
534 Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung
535 Cancer. *Value in Health*; **21**(1), 9-17 (2018).
- 536 40. Hotta K, Kato Y, Leigh N, Takigawa N, Gaafar RM, Kayatani H *et al.* Magnitude of the
537 Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials
538 Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell
539 Lung Cancer: Systematic Review. *Plos One*; **10**(3) (2015).
- 540 41. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Oze I, Ochi N *et al.* Association between
541 incremental gains in the objective response rate and survival improvement in phase III trials
542 of first-line chemotherapy for extensive disease small-cell lung cancer. *Annals of Oncology*;
543 **20**(5), 829-834 (2009).
- 544 42. Ichikawa W, Sasaki Y. Correlation between tumor response to first-line chemotherapy and
545 prognosis in advanced gastric cancer patients. *Annals of Oncology*; **17**(11), 1665-1672 (2006).
- 546 43. Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S *et al.* Progression-free
547 survival as a surrogate endpoint in advanced neuroendocrine neoplasms. *Endocrine-Related*
548 *Cancer*; **24**(9), 475-483 (2017).

- 549 44. Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S *et al.* Alternate
550 Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. *Oncologist*; **24**(1), 47-53
551 (2019).
- 552 45. Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H *et al.* The impact of high
553 PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1
554 antibodies in non-small cell lung cancer. *Lung Cancer*; **128**, 113-119 (2019).
- 555 46. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A *et al.* Response rate
556 or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-
557 small-cell lung cancer: a meta-analysis. *Lancet Oncology*; **7**(9), 741-746 (2006).
- 558 47. Kaufman HL, Schwartz LH, William WN, Jr., Sznol M, Fahrback K, Xu Y *et al.* Evaluation
559 of classical clinical endpoints as surrogates for overall survival in patients treated with
560 immune checkpoint blockers: a systematic review and meta-analysis. *Journal of Cancer
561 Research & Clinical Oncology*; **144**(11), 2245-2261 (2018).
- 562 48. Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized
563 clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete
564 response, time-to-event and overall survival end points. *Annals of Oncology*; **22**(6), 1392-
565 1403 (2011).
- 566 49. Li J, He Q, Yu X, Khan K, Weng XW, Guan MJ. Complete response associated with immune
567 checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine
568 randomized controlled trials. *Cancer Management and Research*; **11**, 1623-1629 (2019).
- 569 50. Li X, Liu S, Gu H, Wang D. Surrogate end points for survival in the target treatment of
570 advanced non-small-cell lung cancer with gefitinib or erlotinib. *Journal of Cancer Research
571 & Clinical Oncology*; **138**(11), 1963-1969 (2012).
- 572 51. Liu L, Chen F, Zhao J, Yu H. Correlation between overall survival and other endpoints in
573 metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of
574 24 randomized trials. *Bulletin du Cancer*; **103**(4), 336-344 (2016).
- 575 52. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M.
576 Correlation between progression free survival and response rate in patients with metastatic
577 colorectal carcinoma. *Cancer*; **91**(11), 2033-2038 (2001).
- 578 53. Makris EA, MacBarb R, Harvey DJ, Poultides GA. Surrogate End Points for Overall
579 Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic
580 Review and Meta-Analysis of 24 Randomized Controlled Trials. *Annals of Surgical
581 Oncology*; **24**(8), 2371-2378 (2017).
- 582 54. Mangal N, Salem AH, Li MY, Menon R, Freise KJ. Relationship between response rates and
583 median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published
584 clinical trials. *Hematological Oncology*; **36**(1), 37-43 (2018).
- 585 55. Mangal N, Salem AH, Menon RM, Freise KJ. Use of depth of response to predict
586 progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results
587 from 102 clinical trials. *Hematological Oncology*; **36**(3), 547-553 (2018).
- 588 56. Moriwaki T, Yamamoto Y, Goshō M, Kobayashi M, Sugaya A, Yamada T *et al.* Correlations
589 of survival with progression-free survival, response rate, and disease control rate in advanced
590 biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy. *British
591 Journal of Cancer*; **114**(8), 881-888 (2016).
- 592 57. Mushti SL, Mulkey F, Sridhara R. Evaluation of Overall Response Rate and Progression-Free
593 Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
594 *Clinical Cancer Research*; **24**(10), 2268-2275 (2018).
- 595 58. Nakashima K, Horita N, Nagai K, Manabe S, Murakami S, Ota E *et al.* Progression-Free
596 Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase

- 597 III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced,
598 Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma. *Journal of Thoracic*
599 *Oncology: Official Publication of the International Association for the Study of Lung Cancer*;
600 **11**(9), 1574-1585 (2016).
- 601 59. Nickolich M, Babakoochi S, Fu P, Dowlati A. Clinical trial design in small cell lung cancer:
602 surrogate end points and statistical evolution. *Clinical Lung Cancer*; **15**(3), 207-212 (2014).
- 603 60. Nie RC, Chen FP, Yuan SQ, Luo YS, Chen S, Chen YM *et al.* Evaluation of objective
604 response, disease control and progression-free survival as surrogate end-points for overall
605 survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. *European*
606 *Journal of Cancer*; **106**, 1-11 (2019).
- 607 61. Pang Y, Shen Z, Sun J, Wang W. Does the use of targeted agents in advanced
608 gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized
609 controlled trials. *Cancer Management and Research*; **10**, 5505-5514 (2018).
- 610 62. Penel N, Ryckewaert T, Kramar A. What is an active regimen in carcinoma of unknown
611 primary sites? Analysis of correlation between activity endpoints reported in phase II trials.
612 Correlation of activity endpoints in phase II trials. *Bulletin du Cancer*; **101**(4), E19-24 (2014).
- 613 63. Petrelli F, Barni S. Surrogate end points and postprogression survival in renal cell carcinoma:
614 an analysis of first-line trials with targeted therapies. *Clinical Genitourinary Cancer*; **11**(4),
615 385-389 (2013).
- 616 64. Petrelli F, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted
617 therapies: an analysis of the first-line phase III trials. *Medical Oncology*; **31**(1), 776 (2014).
- 618 65. Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M *et al.* Defining the most
619 appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced
620 solid cancers a systematic review and meta-analysis. *JAMA Oncology*; **4**(4), 522-528 (2018).
- 621 66. Rose PG, Tian CQ, Bookman MA. Assessment of tumor response as a surrogate endpoint of
622 survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group
623 study. *Gynecologic Oncology*; **117**(2), 324-329 (2010).
- 624 67. Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, Cristofanilli M *et al.* Response rate
625 as a potential surrogate for survival and efficacy in patients treated with novel immune
626 checkpoint inhibitors: A meta-regression of randomised prospective studies. *European*
627 *Journal of Cancer*; **86**, 257-265 (2017).
- 628 68. Sekine I, Tamura T, Kunitoh H, Kubota K, Shinkai T, Kamiya Y *et al.* Progressive disease
629 rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. *Annals of*
630 *Oncology*; **10**(6), 731-733 (1999).
- 631 69. Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A *et al.* Thirty-Month
632 Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An
633 Individual Patient-Level Analysis of Multiple Randomized Trials. *Journal of Clinical*
634 *Oncology*; **35**(5), 552-560 (2017).
- 635 70. Shitara K, Matsuo K, Muro K, Doi T, Ohtsu A. Correlation between overall survival and
636 other endpoints in clinical trials of second-line chemotherapy for patients with advanced
637 gastric cancer. *Gastric Cancer*; **17**(2), 362-370 (2014).
- 638 71. Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG *et al.* Relationship
639 between Overall Survival and Response or Progression-Free Survival in Advanced Non-
640 Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. *Journal of*
641 *Thoracic Oncology: Official Publication of the International Association for the Study of*
642 *Lung Cancer*; **11**(11), 1927-1939 (2016).

- 643 72. Siddiqui MK, Tyczynski J, Pahwa A, Fernandes AW. Objective response rate is a possible
644 surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.
645 *Gynecologic Oncology*; **146**(1), 44-51 (2017).
- 646 73. Sidhu R, Rong A, Dahlberg S. Evaluation of progression-free survival as a surrogate endpoint
647 for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. *Clinical*
648 *Cancer Research*; **19**(5), 969-976 (2013).
- 649 74. Tanaka K, Kawano M, Iwasaki T, Itonaga I, Tsumura H. Surrogacy of intermediate endpoints
650 for overall survival in randomized controlled trials of first-line treatment for advanced soft
651 tissue sarcoma in the pre- and post-pazopanib era: A meta-analytic evaluation. *BMC Cancer*;
652 **19** (1) (no pagination)(56) (2019).
- 653 75. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in
654 metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of
655 first-line chemotherapy. *Journal of Clinical Oncology*; **25**(29), 4562-4568 (2007).
- 656 76. Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y *et al.* Response Rate Is
657 Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer
658 Treated with Gefitinib or Erlotinib. *Journal of Thoracic Oncology*; **4**(8), 994-1001 (2009).
- 659 77. Tsujino K, Shiraishi J, Tsuji T, Kurata T, Kawaguchi T, Kubo A *et al.* Is response rate
660 increment obtained by molecular targeted agents related to survival benefit in the phase III
661 trials of advanced cancer? *Annals of Oncology*; **21**(8), 1668-1674 (2010).
- 662 78. Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Stable disease is not preferentially
663 observed with targeted therapies and as currently defined has limited value in drug
664 development. *Cancer Journal*; **15**(5), 366-373 (2009).
- 665 79. Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while
666 administered and is not a surrogate for overall survival. *Cancer Journal*; **15**(5), 379-385
667 (2009).
- 668 80. Zer A, Prince RM, Amir E, Abdul Razak A. Evolution of Randomized Trials in
669 Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of
670 Reporting. *Journal of Clinical Oncology*; **34**(13), 1469-1475 (2016).
- 671 81. Zhu R, Lu D, Chu YW, Chai A, Green M, Zhang N *et al.* Assessment of Correlation Between
672 Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-
673 Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.
674 *Aaps Journal*; **19**(3), 669-681 (2017).
- 675 82. Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W *et al.* Statistical
676 evaluation of surrogate endpoints with examples from cancer clinical trials. *Biometrical*
677 *Journal*; **58**(1), 104-132 (2016).
- 678 83. Bujkiewicz S, Achana F, Papanikos T, Riley RD, Abrams KR. Technical Support Document
679 20: Multivariate meta-analysis of summary data for combining treatment effects on correlated
680 outcomes and evaluating surrogate endpoints. (2019).

681

682 **Figure legends**

683 Figure 1: PRISMA flow diagram for study inclusion

684 Figure 2: Correlation (r or r_s) between absolute (individual-level) values of ORR and PFS

685 Figure 3: Correlation (r or r_s) between absolute (individual-level) values of ORR and OS


686 Figure 4: Regression R^2 between treatment effects (trial-level) for ORR and PFS

687 Figure 5: Regression R^2 between treatment effects (trial-level) for ORR and OS

688

689

690 **Figure 1: PRISMA flow diagram for study inclusion**



691

692


693 **Table 1: Summary of absolute correlation coefficients and treatment effect R² values**

Surrogate relationship	Range of absolute (individual-level) correlations			Range of treatment effect (trial-level) R ² values		
	N studies	Cancer types and refs	Range of r or r _s across studies and subgroup analyses	N studies	Cancer types and refs	Range of R ² across studies and subgroup analyses
ORR to PFS	12	NSCLC, ^{45,65,78} ovarian, ^{66,72} RCC, ⁶³ NHL, ⁵⁴ SCLC, ⁵⁹ MM, ⁵⁵ CRC, ⁵² CUP, ⁶² NET, ⁴⁴ various ^{65,78}	-0.72 to 0.96	9	NSCLC, ^{21,22,45,67,77} ovarian, ^{27,72} various, ^{67,77,79} CRC ^{26,77}	0.18 to 0.94
ORR to TTP	1	Gastric ⁴²	0.41 to 0.56	0		-
ORR to OS	27	NSCLC, ^{49,50,65,68,71,45,78} CRC, ^{35,52,75} ovarian, ^{66,72} breast, ^{51,64} gastric, ^{42,70} various, ^{65,60,78} pancreatic, ³⁷ RCC, ^{18,63} gastroesophageal, ⁶¹ urothelial, ^{18,19} AML, ²⁰ SCLC, ⁵⁹ glioblastoma, ³⁸ CUP, ⁶² NET ⁴³	-0.40 to 1.00	31	NSCLC, ^{21,22,39,40,45,46,58,67,77} CRC, ^{25,26,29,31,46,73,77} various, ^{47,57,60,67,77,79} pancreatic, ^{28,37,53} SCLC, ^{34,41} RCC, ^{32,63} breast, ^{23,36} ovarian, ²⁷ prostate, ³⁰ BTC, ⁵⁶ STC ⁷⁴	-0.08 to 0.84
CR to PFS	2	SCLC, ⁵⁹ NHL ⁸¹	0.22 to 0.83	1	NHL ⁶⁹	0.45 to 0.93
CR to OS	3	NSCLC, ⁴⁹ SCLC, ⁵⁹ gastroesophageal ⁶¹	-0.04 to 0.62	2	Breast, ³⁶ SCLC ³⁴	0.05 to 0.48
PR to PFS	1	SCLC ⁵⁹	0.35 to 0.70	0		-
PR to OS	1	SCLC ⁵⁹	0.29 to 0.66	0		-
VGPR/CR to PFS	0		(see footnote)*	0		-
DoR to PFS	0		-	0		-
DoR to OS	0		-	0		(see footnote)**

Notes: Further detail on all studies and outcomes is shown in Appendix 5 and Appendix 6. *One study of MM reported the association between VGPR/CR and PFS as adjusted R²=0.64, but this could not be converted to r because it was adjusted.⁵⁵ **Two studies in CRC²⁹ and pancreatic cancer²⁸ reported Spearman correlation coefficients between DoR and OS ranging from 0.40 to 0.76, but these could not be converted to R² as no Pearson correlation coefficients were reported.

AML, acute myeloid leukaemia; BTC, biliary tract cancer; CR, complete response; CRC, colorectal cancer; CUP, cancer of unknown primary; DoR, duration of response; MM, multiple myeloma; NET, neuroendocrine tumour; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; RCC, renal cell carcinoma; SCLC, small cell lung cancer; STC, soft tissue sarcoma; TTP, time to progression; VGPR, very good partial response.


695 **Figure 2: Correlation (r or rs) between absolute (individual-level) values of ORR and PFS**



696

697 For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression. CUP,
 698 cancer of unknown primary; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival; SCLC, small
 699 cell lung cancer.


700 **Figure 3: Correlation (r or rs) between absolute (individual-level) values of ORR and OS**



701

702 For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression.
 703 AML, acute myeloid leukaemia; CUP, cancer of unknown primary; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; SCLC, small cell
 704 lung cancer.


705 **Figure 4: Regression R² between treatment effects (trial-level) for ORR and PFS**



706

707 For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression.
 708 NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival.

709 **Figure 5: Regression R2 between treatment effects (trial-level) for ORR and OS**



710

711 For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression.

712 NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; SCLC, small cell lung cancer.

A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer

Katy Cooper, Paul Tappenden, Anna Cantrell, Kate Ennis

Supplementary Information	Page
Supplementary Information 1: MEDLINE search strategy	2
Supplementary Table 1: IQWiG scoring criteria	3
Supplementary Table 2: BSES2 scoring criteria	3
Supplementary Table 3: Summary of study characteristics	4
Supplementary Table 4: Summary of reported data types	4
Supplementary Table 5: Study characteristics by study	5
Supplementary Table 6: Quality assessment of included meta-reviews	11
Supplementary Table 7: Absolute correlation and regression results per study	14
Supplementary Table 8: Treatment effect correlation and regression results per study	22
Supplementary Table 9: Influence of clinical and study factors on association between ORR and OS	36
Supplementary Table 10: Regression equations for absolute (individual-level) associations	40
Supplementary Table 11: Regression equations for treatment effect (trial-level) associations	41
Supplementary Table 12: Surrogate threshold effect (STE) data reported per study	43
Supplementary Figure 1: IQWiG scores for strength of association across all 202 analyses (within 63 included studies)	44
Supplementary Figure 2: BSES2 scores for strength of association across all 202 analyses (within 63 included studies)	45

Supplementary Information 1: MEDLINE search strategy

Search Strategy (March 2019):

- 1 *Neoplasms/
- 2 (cancer\$ or neoplasm\$ or tumour\$ or tumour\$ or malignan\$ or oncology or lymphoma\$ or sarcoma\$ or melanoma\$ or myeloma\$ or carcinoma\$).tw.
- 3 1 or 2
- 4 tumour response\$.tw.
- 5 tumour response\$.tw.
- 6 objective response\$.tw.
- 7 ORR.tw.
- 8 "duration of response\$.tw.
- 9 dor.tw.
- 10 response rate\$.tw.
- 11 complete response\$.tw
- 12 overall response\$.tw
- 13 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
- 14 3 and 13
- 15 Regression analysis/
- 16 regression.tw.
- 17 relationship.tw.
- 18 correlation.tw.
- 19 prediction.tw.
- 20 association.tw.
- 21 15 or 16 or 17 or 18 or 19 or 20
- 22 14 and 21
- 23 endpoint\$.tw.
- 24 end point\$.tw.
- 25 (surrogate or surrogacy).tw.
- 26 23 or 24 or 25
- 27 22 and 26
- 28 progression-free survival/
- 29 "progression free survival".tw.
- 30 "overall survival".tw.
- 31 (pfs or os).tw.
- 32 "time to progression".tw.
- 33 ttp.tw.
- 34 28 or 29 or 30 or 31 or 32 or 33
- 35 27 and 34
- 36 limit 35 to (english language and humans)

Supplementary Table 1: IQWiG scoring criteria

IQWiG Score	Criteria (based on r for treatment-effect association)*
High	Lower confidence interval of r is ≥ 0.85
Medium+	$r \geq 0.85$ with no reported confidence interval or $r \geq 0.85$ with wide confidence intervals (lower limit < 0.85)
Medium	$0.85 > r \geq 0.7$ and upper confidence interval of r is ≥ 0.7 and lower confidence interval of r is < 0.85 , or $0.85 > r \geq 0.7$ with no reported confidence interval
Low	Upper confidence interval of r is < 0.7 or $r < 0.7$ with no reported confidence interval
Notes: Based on the scoring criteria reported by IQWiG (2011). ¹⁰ *r is defined as any correlation parameter for the treatment-effect association, e.g. Pearson, Spearman, Kendall's Tau. Where no correlation parameter was reported, if a univariate regression was performed and an R^2 value attained, then r (Pearson correlation coefficient) was calculated as the square-root of R^2 . The reported r could be for any treatment effect estimate (hazard ratio, difference in medians, etc.); where more than one was reported, relative estimates (e.g. hazard ratio, odds ratio) were used in preference to difference in medians. The Medium+ category was based on the approach used in Savina <i>et al.</i> ¹⁴	

Supplementary Table 2: BSES2 scoring criteria

BSES2 score	Criteria (based on R^2 for both treatment effect and individual-level associations)*
Excellent	R^2 (treatment effect) ≥ 0.6 and R^2 (absolute) ≥ 0.6
Good	R^2 (treatment effect) ≥ 0.4 and R^2 (absolute) ≥ 0.4
Fair	R^2 (treatment effect) ≥ 0.2 and R^2 (absolute) ≥ 0.2
Poor	R^2 (treatment effect) < 0.2 and/or R^2 (absolute) < 0.2
Notes: Based on the scoring criteria reported by Lassere <i>et al.</i> (2012). ¹¹ * R^2 is the coefficient of determination for a regression analysis. Where R^2 was not reported, it was calculated as the square of the Pearson correlation coefficient (r), if available. The reported R^2 could be for any treatment effect estimate (hazard ratio, difference in medians, etc.); where more than one was reported, relative estimates (e.g. hazard ratio, odds ratio) were used in preference to difference in medians.	

1 **Supplementary Table 3: Summary of study characteristics**

Surrogate relationship	N	Cancer type	N	Disease stage	N	Line of treatment	N	Treatment type	N
ORR to OS	57	Lung (NSCLC)	16	Advanced/metastatic	43	1st	23	Chemo	21
ORR to PFS	22	Colorectal	10	Unclear	9	All / various	18	Immune checkpoint inhibitors	9
CR to OS	8	Various solid	8	Advanced, locally advanced, unresectable or metastatic	2	NR	8	Targeted	8
CR to PFS	7	Breast	5			1st + 2nd	5	Various	7
DoR to OS	2	NHL	4	Extensive disease	2	2nd	4	Systemic	5
ORR to TTP	1	Lung (SCLC)	3	Limited or extensive disease	1	2nd + subsequent	3	Chemo or targeted	3
PR to PFS	1	Ovarian	3	Advanced or recurrent	1	2nd + 3rd	2	Chemo, immune or targeted	2
PR to OS	1	Pancreatic	3	Advanced, locally advanced or recurrent	1			NR	1
VGPR/CR to PFS	1	Renal cell	3					Chemo + targeted	1
DoR to PFS	1	Gastric	2	Relapsed / refractory	1			Chemo or immune	1
		Neuroendocrine	2	Most stage III/IV	1			Chemo, hormonal + targeted	1
		Soft tissue sarcoma	2	Recurrent / platinum-resistant	1			Chemo or biologic	1
		Urothelial	2	Various	1			Cytokine or targeted	1
		AML	1					Gemcitabine + chemo or targeted	1
		Biliary tract	1					Bevacizumab + chemo	1
		Gastroesophageal	1						
		Glioblastoma	1						
		Multiple myeloma	1						
		Prostate	1						
		Unknown primary	1						

Note: Ns may sum to more than total number of studies (N=63) as some studies reported more than one surrogate relationship or cancer type. AML, acute myeloid leukaemia; chemo, chemotherapy; CR, complete response; DoR, duration of response; immune, immunotherapy; NR, not reported; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SCLC, small cell lung cancer; TTP, time to progression; VGPR, very good partial response.

2

3 **Supplementary Table 4: Summary of reported data types**

N primary studies per meta-regression (range)	N patients per meta-regression (range)	Included study types per meta-regression	Data types	Absolute association reported?	Treatment effect association reported?	STE reported?
4 to 191	407 to 44,125	RCT only (N=44) RCT+SA (N=17) SA only (N=2)	AD (N=58) IPD (N=5)	N=32	N=38	N=4

AD, aggregate data; IPD, individual patient data; RCT, randomised controlled trials; SA, single-arm studies; STE, surrogate threshold effect.

4

5 Supplementary Table 5: Study characteristics by study

Reference	Cancer	Surrogate outcome	Final outcome	Stage	Line	Treatment	N studies	N patients	Study types	Publication/search years	Data type	Response criteria	Absolute association	Treatment effect association	STE reported
Agarwal 2017 ²⁰	Acute myeloid leukemia	ORR CR	OS	Various	1st	Systemic	20 [†]	NR	RCT + SA	2004-2016	AD	NR	Y		
Moriwaki 2016 ⁵⁶	Biliary tract	ORR	OS	Advanced	1st	Chemo	17 [†]	2040	RCT	Up to 2015	AD	NR		Y	
Bruzzi 2005 ²³	Breast	ORR	OS	Metastatic	All	Chemo	10	2126	RCT	1991-2001	IPD	WHO (8), ECOG (1), NR (1)		Y	
Burzykowski 2008 ²⁴	Breast	ORR	PFS OS	Metastatic	1st	Chemo	11	3953	RCT	1999-2008	IPD	WHO		Y	
Hackshaw 2005 ³⁶	Breast	ORR CR	OS	Metastatic	1st	Chemo	42*	9163	RCT	1966-2005	AD	NR		Y	
Liu 2016 ⁵¹	Breast	ORR*	OS	Metastatic	2nd + 3rd	Chemo	24	8617	RCT	1999 to 2014	AD	NR	Y		
Petrelli 2014 ⁶⁴	Breast	ORR	OS	Metastatic or advanced	1st	Targeted + chemo	20 [†]	10138 [†]	RCT	2000 to 2012	AD	NR	Y		
Buyse 2000 ²⁵	Colorectal	ORR	OS	Advanced	1st	Chemo	25	3791	RCT	Collected 1990-1996	IPD	WHO		Y	
Ciani 2015 ²⁶ Elia 2018 ³³	Colorectal	ORR	PFS OS	Advanced or metastatic	All	Systemic	33	NR	RCT	2003-2013	AD	RECIST or WHO		Y	Y
Colloca 2016b ²⁹	Colorectal	ORR DoR	OS	Metastatic	1st	Bevacizumab + chemo	11	NR	RCT	2000-2014	AD	RECIST		Y	
Giessen 2015 ³⁵	Colorectal	ORR	OS	Metastatic	2nd	Chemo	22	10509	RCT	2000-2013	AD	RECIST (17), WHO (5)	Y		
Cremolini 2017 ³¹	Colorectal	ORR	OS	Metastatic	2nd	Targeted	20*	7571	RCT	To 2015	AD	NR		Y	
Johnson 2006 ⁴⁶	Colorectal	ORR	OS	Metastatic	1st	Chemo	146 [†]	35337 [†]	RCT	To 2005	AD	NR (very few RECIST)		Y	
Louvet 2001 ⁵²	Colorectal	ORR	PFS OS	Metastatic	1st	Various	29	13498	RCT	1990 to 2000	AD	NR	Y		
Sidhu 2013 ⁷³	Colorectal	ORR	OS	Metastatic	1st (most)	Chemo +/- targeted	24 [†]	20438 [†]	RCT	2000 to 2011	AD	NR		Y	
Tang 2007 ⁷⁵	Colorectal	ORR	OS	Metastatic	1st	Chemo	39	18668	RCT	1990 to 2005	AD	NR	Y	Y	
Tsujino 2010 ⁷⁷	Colorectal	ORR	PFS OS	Advanced	NR	Targeted	7	NR	RCT	Up to 2009	AD	NR		Y	
Ichikawa 2006 ⁴²	Gastric	ORR	TTP OS	Advanced	1st	Chemo	25	4593	RCT	NR	AD	WHO, SWOG, RECIST, Japan	Y		
Shitara 2014 ⁷⁰	Gastric	ORR*	OS	Advanced	2nd + 3rd	Chemo	64	4286	RCT + SA	2002 to 2012/2013	AD	NR	Y		

Reference	Cancer	Surrogate outcome	Final outcome	Stage	Line	Treatment	N studies	N patients	Study types	Publication/search years	Data type	Response criteria	Absolute association	Treatment effect association	STE reported
Pang 2018 ⁶¹	Gastroesophageal	ORR* CR	OS	Advanced	1st + 2nd	Targeted	18	7892	RCT	Up to 2018	AD	RECIST	Y		
Han 2014 ³⁸	Glioblastoma	ORR	OS	Unclear	Various	Various	91 [†]	7125 [†]	RCT + SA	1991-2012	AD	NR ("standard criteria")	Y		
Blumenthal 2017 ²²	Lung (NSCLC)	ORR	PFS OS	Metastatic	Various	Chemo, immune or targeted	25	20013 [†]	RCT	2003-2016	AD	RECIST or WHO		Y	
Blumenthal 2015 ²¹	Lung (NSCLC)	ORR	PFS OS	Metastatic	Various	Chemo or targeted	14	12567 [†]	RCT	2003-2013	AD	RECIST (11) or WHO (3)		Y	
Hashim 2018 ³⁹	Lung (NSCLC)	ORR	OS	Advanced	2nd + subsequent	Various	140	41725	RCT	To 2016	AD	NR		Y	Y
Hotta 2015 ⁴⁰	Lung (NSCLC)	ORR	OS	Advanced	Various	Targeted	18	7633 [†]	RCT	2003-2014	AD	NR		Y	
Ito 2019 ⁴⁵	Lung (NSCLC)	ORR	PFS OS	Advanced	Various	Immune checkpoint inhibitors (PD-(L)1)	7	3752 [†]	RCT	NR	AD	NR	Y	Y	
Johnson 2006 ⁴⁶	Lung (NSCLC)	ORR	OS	Advanced	1st	Chemo	191 [†]	44125 [†]	RCT	To 2005	AD	NR (very few RECIST)		Y	
Li 2019 ⁴⁹	Lung (NSCLC)	ORR* CR	OS	Advanced	1st + 2nd	Immune checkpoint inhibitors	5 [†]	4803 [†]	RCT	Up to 2018	AD	RECIST	Y		
Li 2012 ⁵⁰	Lung (NSCLC)	ORR	OS	Advanced	1st + 2nd	Targeted	60	9903	RCT + SA	Up to 2011	AD	RECIST (52), WHO (10)	Y		
Nakashima 2016 ⁵⁸	Lung (NSCLC)	ORR	OS	Advanced, locally advanced and recurrent	1st	Chemo	44	22709	RCT	2005 to 2015	AD	RECIST		Y	
Ritchie 2018 ⁶⁵	Lung (NSCLC)	ORR* OS	PFS OS	Advanced	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	8	NR	RCT	2000 to 2017	AD	NR	Y	Y	
Roviello 2017 ⁶⁷	Lung (NSCLC)	ORR	PFS OS	Unclear	Various	Immune checkpoint inhibitors	7*	3369*	RCT	Up to 2017	AD	RECIST or mWHO		Y	
Sekine 1999 ⁶⁸	Lung (NSCLC)	ORR	OS	Unclear	Various	Chemo	42	1935	SA +1 RCT	1988-1997	AD	WHO	Y		

Reference	Cancer	Surrogate outcome	Final outcome	Stage	Line	Treatment	N studies	N patients	Study types	Publication/search years	Data type	Response criteria	Absolute association	Treatment effect association	STE reported
Shukuya 2016 ⁷¹	Lung (NSCLC)	ORR	OS	Advanced	All	a) Immune checkpoint inhibitors (PD-(L)1) b) Chemo (docetaxel)	a) 10 [†] b) 22 [†]	NR	RCT + SA	2012 to 2016	AD	RECIST (most)	Y		
Tsujino 2010 ⁷⁷	Lung (NSCLC)	ORR	PFS OS	Advanced	NR	Targeted	6	NR	RCT	Up to 2009	AD	NR		Y	
Tsujino 2009 ⁷⁶	Lung (NSCLC)	ORR	PFS OS	Advanced	NR	Targeted	28	6171	RCT + SA	To 2007	AD	RECIST (21), WHO (9)	Y		
Vidaurre 2009 ⁷⁸	Lung (NSCLC)	ORR*	PFS OS	Advanced, locally advanced, unresectable or metastatic	NR	Chemo or targeted	35	NR	RCT + SA	2006 to 2008	AD	NR	Y		
Foster 2011 ³⁴	Lung (SCLC)	ORR CR	OS	Extensive-stage	1st	Chemo	3 RCTs (32 centres)	596 [†]	RCT	Trials initiated 1987-1999	AD	NR (CR=disappearance; PR ≥50% reduction)		Y	
Hotta 2009 ⁴¹	Lung (SCLC)	ORR	OS	Extensive disease	1st	Chemo	48	8779	RCT	1990-2008	AD	WHO (23), ECOG (2), RECIST (1), Japan (1), or NR		Y	
Nickolich 2014 ⁵⁹	Lung (SCLC)	ORR CR PR	PFS OS	Limited or extensive disease	1st + 2nd + maintenance	Various	66 [†]	8471 [†]	RCT + SA	1983 to 2010	AD	NR	Y		
Mangal 2018 ⁵⁵ (myeloma)	Multiple myeloma	ORR* CR VGPR or CR	PFS	Relapsed / refractory	2nd + subsequent	Various	79 [†]	13322 [†]	RCT + SA	1999 to 2016	AD	IMWG	Y		
Imaoka 2019 ⁴⁴	Neuroendocrine	ORR	PFS	Advanced	Various	Systemic	22	1310	RCT + SA	1996-2016	AD	RECIST (20), WHO (2)	Y		
Imaoka 2017 ⁴³	Neuroendocrine	ORR	OS	Advanced	Various	Systemic	20	2530	RCT + SA	1996-2016	AD	NR	Y		
Lee 2011 ⁴⁸	NHL (aggressive)	CR	PFS OS	Unclear	1st	Chemo	36 [†]	16103 [†]	RCT	1990-2009	AD	NR		Y	
Lee 2011 ⁴⁸	NHL (indolent)	CR	PFS OS	Unclear	1st	Chemo	15 [†]	5128 [†]	RCT	1990-2009	AD	NR		Y	

Reference	Cancer	Surrogate outcome	Final outcome	Stage	Line	Treatment	N studies	N patients	Study types	Publication/search years	Data type	Response criteria	Absolute association	Treatment effect association	STE reported
Mangal 2018 ⁵⁴ (NHL)	NHL	ORR* CR	PFS	Stage III/IV >75% in most cohorts	Various	Various	73	6071	RCT + SA	1996 to 2015	AD	NR	Y		
Shi 2017 ⁶⁹	NHL (indolent; follicular)	CR 30mo CR 24mo	PFS	Unclear	1st	Chemo or immuno (induction or maintenance)	13	3837	RCT	1990 to 2011	IPD	NR (CR=disappearance)		Y	Y
Zhu 2017 ⁸¹	NHL (indolent; follicular)	CR	PFS	Unclear	NR	Chemo, immune or targeted	13	NR	RCT + SA	1993 to 2013	AD	NR	Y		
Zhu 2017 ⁸¹	NHL (mantle cell)	CR	PFS	Unclear	NR	Chemo, immune or targeted	NR	NR	RCT + SA	1993 to 2013	AD	NR	Y		
Colloca & Venturino 2017 ²⁷	Ovarian	ORR CR	PFS OS	Advanced	1st	Chemo	29	NR	RCT	1990-2016	AD	WHO (24), RECIST (8)		Y	
Rose 2010 ⁶⁶	Ovarian	ORR*	PFS OS	Recurrent / platinum-resistant	2nd	Various	11	407	SA	1994 to 2004	IPD	WHO (10), RECIST (1)	Y		
Siddiqui 2017 ⁷²	Ovarian	ORR*	PFS OS	Advanced, recurrent	2nd + subsequent	Chemo	39 [†]	9223 [†]	RCT	2000 to 2015	AD	NR	Y	Y	
Colloca 2016a ²⁸	Pancreatic	ORR DoR	PFS OS	Advanced or metastatic	1st	Gemcitabine + chemo or targeted	36*	NR	RCT	1997-2014	AD	RECIST		Y	
Hamada 2016 ³⁷	Pancreatic	ORR	OS	Advanced	1st	Chemo	47	15906 [†]	RCT	1995-2015	AD	NR	Y	Y	
Makris 2017 ⁵³	Pancreatic (adenocarcinoma)	ORR	OS	Locally advanced, unresectable or metastatic	1st	Chemo (gemcitabine)	22*	10379*	RCT	2000 to 2015	AD	NR (RR=shrinkage or disappearance)		Y	
Colloca 2016c ³⁰	Prostate	ORR	OS	Metastatic (castration-resistant)	1st + 2nd	Chemo, hormonal + targeted	17	NR	RCT	1995-2014	AD	NR (CR=disappearance; PR= \geq 30% reduction)		Y	
Abdel-Rahman 2018 ¹⁸	Renal cell	ORR	OS	Advanced	Various	Immune checkpoint inhibitors (PD-(L)1)	4	1093	RCT + SA	To 2017	AD	RECIST	Y		

Reference	Cancer	Surrogate outcome	Final outcome	Stage	Line	Treatment	N studies	N patients	Study types	Publication/search years	Data type	Response criteria	Absolute association	Treatment effect association	STE reported
Delea 2012 ³²	Renal cell	ORR	OS	Metastatic	NR	Cytokine or targeted	25*	10943 [†]	RCT	1997-2010	AD	NR		Y	
Petrelli 2013 ⁶³	Renal cell	ORR	PFS OS	Metastatic	1st	Targeted	6 [†]	3188 [†]	RCT	Up to 2011	AD	NR	Y	Y	
Tanaka 2019 ⁷⁴	Soft tissue sarcoma	ORR	OS	Advanced	1st	Chemo	27 [†]	6156 [†]	RCT	1974 to 2017	AD	NR		Y	
Zer 2016 ⁸⁰	Soft tissue sarcoma	ORR	OS	Advanced or metastatic	All	Systemic	52 [†]	9762 [†]	RCT	1974 to 2014	AD	NR		Y	
Penel 2014 ⁶²	Unknown primary	ORR*	PFS OS	Unclear	NR	NR	38 [†]	NR	SA	1997 to 2011	AD	RECIST or WHO	Y		
Abdel-Rahman 2018 ¹⁸	Urothelial	ORR	OS	Advanced	Various	Immune checkpoint inhibitors (PD-(L)1)	9	1699	RCT + SA	To 2017	AD	RECIST	Y		
Agarwal 2014 ¹⁹	Urothelial	ORR	OS	Advanced (operable or metastatic)	2nd	Chemo or biologic	10	560	RCT + SA	NR	AD	RECIST	Y		
Kaufman 2018 ⁴⁷	Various solid tumours	ORR	OS	Unclear	Various	Immune checkpoint inhibitors +/- chemo	27 [†]	10300 [†]	RCT	2005-2017	AD	RECIST or mWHO		Y	
Mushti 2018 ⁵⁷	Various solid tumours	ORR*	OS	Unclear	NR	Immune checkpoint inhibitors (PD-(L)1)	13	6722	RCT	2014 to 2016	AD	RECIST		Y	
Nie 2019 ⁶⁰	Various solid tumours	ORR*	OS	Advanced or recurrent	Various	Immune checkpoint inhibitors (PD-(L)1)	43 [†]	15088 [†]	RCT + SA	Up to 2018	AD	RECIST	Y	Y	
Ritchie 2018 ⁶⁵	Various solid tumours	ORR*	PFS OS	Advanced	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	20 [†]	10828 [†]	RCT	2000 to 2017	AD	NR	Y	Y	
Roviello 2017 ⁶⁷	Various solid tumours	ORR	PFS OS	Unclear	Various	Immune checkpoint inhibitors	17 [†]	8994 [†]	RCT	Up to 2017	AD	RECIST or mWHO		Y	
Tsujino 2010 ⁷⁷	Various solid tumours	ORR	PFS OS	Advanced	NR	Targeted	18	NR	RCT	Up to 2009	AD	NR		Y	Y

Reference	Cancer	Surrogate outcome	Final outcome	Stage	Line	Treatment	N studies	N patients	Study types	Publication/search years	Data type	Response criteria	Absolute association	Treatment effect association	STE reported
Vidaurre 2009 ⁷⁸	Various	ORR*	PFS OS	Advanced, locally advanced, unresectable or metastatic	NR	Chemo or targeted	143 [†]	6974 [†]	RCT + SA	2006 to 2008	AD	NR	Y		
Wilkerson+ Fojo 2009 ⁷⁹	Various solid tumours	ORR	PFS OS	Metastatic	NR	NR	66 [†]	NR	RCT	NR	AD	NR		Y	

Note: Of the 63 included studies (64 refs), 8 references^{18,46,48,65,67,77,78,81} appear on 2-3 rows as they report on 2-3 different cancer types. *Calculated from reported data. [†]Unclear for individual subgroups.

AD, aggregate data; chemo, chemotherapy; CR, complete response; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; IMWG, International Myeloma Working Group (criteria); IPD, individual patient data; mo, months; mWHO, modified World Health Organisation (criteria); NHL, non-Hodgkin's lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; ORR, overall response rate (ORR=PR+CR); OS, overall survival; PFS, progression-free survival; PR, partial response; RCT, randomised controlled trials; RECIST, Response Evaluation Criteria In Solid Tumours; SA, single-arm studies; SCLC, small cell lung cancer; STE, surrogate threshold effect; TTP, time to progression; VGPR, very good partial response; WHO, World Health Organisation (criteria).

7 Supplementary Table 6: Quality assessment of included meta-reviews

Reference	Cancer	Inclusion criteria clear & relevant (population, outcomes, study type)	Literature search comprehensive (at least 2 databases or other sources AND keywords provided)	Duplicate study selection (all or a sample)	Duplicate data extraction or data checking	Risk of bias assessment reported	Analysis methods appropriate: correlation coefficient (r or rs) and/or coefficient of determination (R2)	Heterogeneity explored through subgroup analyses	Uncertainty assessed (reports 95% confidence intervals for r, rs or R2)
Agarwal 2017 ²⁰	AML	Y	N (PubMed only)	U	U	N	Y	N	N
Moriwaki 2016 ⁵⁶	Biliary tract	Y	Y	U	Y	N	Y	Y	Y
Bruzzi 2005 ²³	Breast	Y	Y	U	Y	N	Y	N	Y
Burzykowski 2008 ²⁴	Breast	Y	N	U	U	N	Y	N	Y
Hackshaw 2005 ³⁶	Breast	Y	N (Medline only)	U	U	N	Y	Y	N
Liu 2016 ⁵¹	Breast	Y	Y	Y	Y	N	Y	Y	Y
Petrelli 2014 ⁶⁴	Breast	Y	Y	U	U	N	Y	N	Y
Buyse 2000 ²⁵	Colorectal	Y	U	U	Y	N	Y	N	Y
Ciani 2015 ²⁶ Elia 2018 ³³	Colorectal	Y	Y	Y	Y	Y	Y	Y	Y
Colloca 2016b ²⁹	Colorectal	Y	Y	U	U	N	Y	N	N
Giessen 2015 ³⁵	Colorectal	Y	Y	U	U	N	Y	N	Y
Cremolini 2017 ³¹	Colorectal	Y	Y	U	Y	N	Y	Y	N
Johnson 2006 ⁴⁶	Colorectal Lung (NSCLC)	Y	Y	N	Y	Y	Y	N	N
Louvet 2001 ⁵²	Colorectal	Y	U	U	U	N	Y	N	N
Sidhu 2013 ⁷³	Colorectal	Y	Y	U	U	N	Y	Y	Y
Tang 2007 ⁷⁵	Colorectal	Y	Y	U	U	N	Y	N	Y
Tsujino 2010 ⁷⁷	Colorectal Lung (NSCLC) Various tumours	Y	N (PubMed only)	U	Y	N	Y	N	N
Ichikawa 2006 ⁴²	Gastric	Y	Y	U	U	N	Y	Y	N
Shitara 2014 ⁷⁰	Gastric	Y	Y	U	U	N	Y	N	Y
Pang 2018 ⁶¹	Gastroesophageal	Y	N (search terms NR)	U	Y	Y	Y	N	N
Han 2014 ³⁸	Glioblastoma	Y	Y	U	U	N	Y	N	Y
Blumenthal 2017 ²²	Lung (NSCLC)	Y	N (trials submitted to FDA rather than search)	U	U	N	Y	N	Y
Blumenthal 2015 ²¹	Lung (NSCLC)	Y	N (FDA trials not search)	U	U	N	Y	Y	Y

Reference	Cancer	Inclusion criteria clear & relevant (population, outcomes, study type)	Literature search comprehensive (at least 2 databases or other sources AND keywords provided)	Duplicate study selection (all or a sample)	Duplicate data extraction or data checking	Risk of bias assessment reported	Analysis methods appropriate: correlation coefficient (r or rs) and/or coefficient of determination (R2)	Heterogeneity explored through subgroup analyses	Uncertainty assessed (reports 95% confidence intervals for r, rs or R2)
Hashim 2018 ³⁹	Lung (NSCLC)	Y	Y	Y	Y	Y	Y	Y	Y
Hotta 2015 ⁴⁰	Lung (NSCLC)	Y	Y	U	Y	N	Y	Y	N
Ito 2019 ⁴⁵	Lung (NSCLC)	Y	Y	Y	U	N	Y	Y	N
Li 2019 ⁴⁹	Lung (NSCLC)	Y	N (search terms NR)	U	Y	Y	Y	N	N
Li 2012 ⁵⁰	Lung (NSCLC)	Y	Y	Y	Y	N	Y	N	N
Nakashima 2016 ⁵⁸	Lung (NSCLC)	Y	Y	Y	Y	Y	Y	N	N
Ritchie 2018 ⁶⁵	Lung (NSCLC) Various tumours	Y	Y	U	Y	Y	Y	N	Y
Roviello 2017 ⁶⁷	Lung (NSCLC) Various tumours	Y	Y	Y	Y	N	Y	Y (for various)	Y
Sekine 1999 ⁶⁸	Lung (NSCLC)	Y	Y	U	U	N	Y	N	N
Shukuya 2016 ⁷¹	Lung (NSCLC)	Y	Y	U	Y	N	Y	Y	N
Tsujino 2009 ⁷⁶	Lung (NSCLC)	Y	Y	U	U	N	N (slope only)	N	N
Vidaurre 2009 ⁷⁸	Lung (NSCLC) Various	Y	N (trials in 5 journals rather than search)	U	Y	N	Y	Y (for various)	N
Foster 2011 ³⁴	Lung (SCLC)	Y	N (trials by 1 group rather than search)	U	U	N	Y	N	N
Hotta 2009 ⁴¹	Lung (SCLC)	Y	Y	U	Y	N	Y	Y	N
Nickolich 2014 ⁵⁹	Lung (SCLC)	Y	N (trials in 1 journal rather than search)	U	Y	N	Y	Y	N
Mangal 2018 ⁵⁵ (myeloma)	Multiple myeloma (myeloma)	Y	Y	U	U	N	Y	N	N
Imaoka 2019 ⁴⁴	Neuroendocrine	Y	Y	Y	U	N	Y	Y	Y
Imaoka 2017 ⁴³	Neuroendocrine	Y	Y	Y	U	N	Y	N	Y
Lee 2011 ⁴⁸	NHL (aggressive) NHL (indolent)	Y	Y	U	U	N	Y	N	Y
Mangal 2018 ⁵⁴ (NHL)	NHL	Y	Y	U	U	N	Y	N	N
Shi 2017 ⁶⁹	NHL (follicular)	Y	Y	U	U	N	Y	Y	Y
Zhu 2017 ⁸¹	NHL (follicular) NHL (mantle cell)	Y	Y	U	U	N	Y	N	Y

Reference	Cancer	Inclusion criteria clear & relevant (population, outcomes, study type)	Literature search comprehensive (at least 2 databases or other sources AND keywords provided)	Duplicate study selection (all or a sample)	Duplicate data extraction or data checking	Risk of bias assessment reported	Analysis methods appropriate: correlation coefficient (r or rs) and/or coefficient of determination (R2)	Heterogeneity explored through subgroup analyses	Uncertainty assessed (reports 95% confidence intervals for r, rs or R2)
Colloca & Venturino 2017 ²⁷	Ovarian	Y	Y	Y	U	N	Y	Y	N
Rose 2010 ⁶⁶	Ovarian	Y	N (trials by 1 group rather than search)	N	U	N	Y	N	N
Siddiqui 2017 ⁷²	Ovarian	Y	Y	U	Y	N	Y	N	N
Colloca 2016a ²⁸	Pancreatic	Y	N (PubMed only)	Y	U	N	Y	Y	N
Hamada 2016 ³⁷	Pancreatic	Y	Y	Y	Y	N	Y	N	Y
Makris 2017 ⁵³	Pancreatic (adenocarcinoma)	Y	N (search terms NR)	Y	Y	N	Y	N	Y
Colloca 2016c ³⁰	Prostate	Y	N (PubMed only)	Y	Y	N	Y	Y	N
Abdel-Rahman 2018 ¹⁸	Renal cell Urothelial	Y	Y	U	U	N	Y	N	N
Delea 2012 ³²	Renal cell	Y	N (search terms NR)	Y	U	N	Y	N	N
Petrelli 2013 ⁶³	Renal cell	Y	Y	U	Y	N	Y	N	N
Tanaka 2019 ⁷⁴	Soft tissue sarcoma	Y	Y	U	Y	N	Y	N	Y
Zer 2016 ⁸⁰	Soft tissue sarcoma	Y	Y	U	Y	Y	Y	N	N
Penel 2014 ⁶²	Unknown primary	Y	N (Medline only; search terms NR)	U	U	N	Y	N	N
Agarwal 2014 ¹⁹	Urothelial	Y	N (search methods NR)	U	U	N	Y	Y	N
Kaufman 2018 ⁴⁷	Various tumours	Y	Y	Y	Y	N	Y	Y	N
Mushti 2018 ⁵⁷	Various tumours	Y	N (FDA trials not search)	U	U	N	Y	N	N
Nie 2019 ⁶⁰	Various tumours	Y	Y	Y	Y	N	Y	N	N
Wilkerson+Fojo 2009 ⁷⁹	Various tumours	Y	N (search methods NR)	U	Y	N	Y	N	N

AML, acute myeloid leukaemia; N, No; NHL, non-Hodgkin's lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; U, Unclear; Y; Yes.

9 Supplementary Table 7: Absolute correlation and regression results per study

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
ORR vs. PFS (or TTP)												
Louvet 2001 ⁵²	ORR	PFS	Colorectal	1st	Various	29	13498	Spearman (ORR vs. med PFS)	rs=0.66, p<0.0001	LR (ORR vs. med PFS)		PFS = 3.2 + 0.1 * ORR
Ichikawa 2006 ⁴²	ORR	TTP	Gastric	1st	Chemo (any)	12*	2144	Spearman, wtd O(RR vs. med TTP)	rs=0.49, p<0.0001	WLR (ORR vs. med TTP)		TTP = 1.73 + 0.09 * ORR
Ichikawa 2006 ⁴²	ORR	TTP	Gastric	1st	Chemo (novel)	8*	1077	Spearman, wtd (ORR vs. med TTP)	rs=0.41, p=0.018			
Ichikawa 2006 ⁴²	ORR	TTP	Gastric	1st	Chemo (non-novel)	7*	1067	Spearman, wtd (ORR vs. med TTP)	rs=0.56, p=0.0053			
Ito 2019 ⁴⁵	ORR	PFS	Lung (NSCLC)	Various	Immune checkpoint inhibitors (PD-(L)1)	6	3752 [†]	a) Pearson, wtd b) Spearman, wtd (ORR vs. med PFS)	a) r=0.55, p<0.0001 b) rs=0.33, p<0.0001	WLR R2 (ORR vs. med PFS)	R2=0.30, p=0.206	
Ito 2019 ⁴⁵	ORR	PFS	Lung (NSCLC)	- Various - High PD-L1 expression	Immune checkpoint inhibitors (PD-(L)1)	7	1381	a) Pearson, wtd b) Spearman, wtd (ORR vs. med PFS)	a) r=0.90, p<0.0001 b) rs=0.48, p<0.0001	WLR R2 (ORR vs. med PFS)	R2=0.81, p=0.006	
Ritchie 2018 ⁶⁵	ORR	PFS	Lung (NSCLC)	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	8	NR	Correlation (NR) (ORR vs. 6mo PFS)	r=0.85 (0.63 to 1.06), p=NR			
Tsujino 2009 ⁷⁶	ORR	PFS	Lung (NSCLC)	NR	Targeted	18*	3790*			LR (ORR vs. med PFS)	R2=NR, p=0.001	Slope 0.072
Vidaurre 2009 ⁷⁸	ORR	PFS	Lung (NSCLC)	NR	Chemo or targeted	35	NR			Regression (NR) (ORR vs. med PFS)	R2=0.75, p<0.0001	
Nickolich 2014 ⁵⁹	ORR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited or extensive	Various	66 [†]	8471 [†]	Pearson (ORR vs. med PFS)	r=0.73, p<0.0001			
Nickolich 2014 ⁵⁹	ORR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited disease	Various	66 [†]	8471 [†]	Pearson (ORR vs. med PFS)	r=0.02, p=0.978			
Nickolich 2014 ⁵⁹	ORR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Extensive disease	Various	66 [†]	8471 [†]	Pearson (ORR vs. med PFS)	r=0.51, p=0.013			

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
Mangal 2018 ⁵⁵ (myeloma)	ORR	PFS	Multiple myeloma	2nd +	Various	79 [†]	13322 [†]			WLR adj R2 (logit ORR vs. log med PFS)	Adj R2=0.50, p=NR	
Imaoka 2019 ⁴⁴	ORR	PFS	Neuroendocrine	Various	Systemic	22	1310	Pearson (ORR vs. med PFS)	r=0.37 (-0.05 to 0.80), p=0.085			
Imaoka 2019 ⁴⁴	ORR	PFS	Neuroendocrine	- Various - Published 1996-2010	Systemic	6*	NR	Pearson (ORR vs. med PFS)	r= -0.08 (-0.76 to 0.60), p=0.824			
Imaoka 2019 ⁴⁴	ORR	PFS	Neuroendocrine	- Various - Published 2011-2016	Systemic	16*	NR	Pearson (ORR vs. med PFS)	r=0.43 (-0.07 to 0.93), p=0.095			
Imaoka 2019 ⁴⁴	ORR	PFS	Neuroendocrine	Various	Cytotoxic	9 arms	NR	Pearson (ORR vs. med PFS)	r=0.63 (0.03 to 1.22), p=0.041			
Imaoka 2019 ⁴⁴	ORR	PFS	Neuroendocrine	Various	Non-cytotoxic	18 arms	NR	Pearson (ORR vs. med PFS)	r=0.18 (-0.27 to 0.62), p=0.432			
Imaoka 2019 ⁴⁴	ORR	PFS	Neuroendocrine	Various	Targeted	19 arms	NR	Pearson (ORR vs. med PFS)	r=0.42 (-0.06 to 0.90), p=0.086			
Imaoka 2019 ⁴⁴	ORR	PFS	Neuroendocrine	Various	Non-targeted	8 arms	NR	Pearson (ORR vs. med PFS)	r= -0.72 (-1.09 to -0.35), p<0.001			
Mangal 2018 ⁵⁴ (NHL)	ORR	PFS	NHL	Various	Various	73	6071			LR adj R2 (logit ORR vs. log med PFS)	Adj R2=0.70, p=NR	log (med PFS) = 1.97 + 0.414 * logit (ORR)
Rose 2010 ⁶⁶	ORR	PFS	Ovarian	2nd	Various	11	407	a) Pearson b) Kendall Tau-b (ORR vs. med PFS)	a) r=0.62, p=0.044 b) r=0.48, p=0.042			
Siddiqui 2017 ⁷²	ORR	PFS	Ovarian	2nd +	Chemo	39 [†]	9223 [†]	a) Pearson, wtd (ORR vs. med PFS) b) Pearson, unwt (ORR vs. med PFS)	a) r=0.85, p<0.001 b) 0.76, p<0.001	WLR R2 (ORR vs. med PFS): a) unadj b) adj	a) R2=0.72, p=NR b) adj R2=0.72, p=NR	med PFS = 2.59 + 0.12 * ORR
Petrelli 2013 ⁶³	ORR	PFS	Renal cell	1st	Targeted	6 [†]	3188 [†]	Spearman, wtd (ORR vs. med PFS)	rs=0.96, p<0.0001			
Penel 2014 ⁶²	ORR	PFS	Unknown primary	NR	NR	38 [†]	NR	Pearson via WLR (ORR v. med PFS)	r=0.54, p<0.0001			
Ritchie 2018 ⁶⁵	ORR	PFS	Various solid tumours	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	20 [†]	10828 [†]	Correlation (NR) (ORR vs. 6mo PFS)	r=0.37 (0.06 to 0.95), p=NR			

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
Vidaurre 2009 ⁷⁸	ORR	PFS	Various	NR	Chemo	85	3982*			Regression (NR) (ORR vs. med PFS)	R2=0.53, p<0.0001	
Vidaurre 2009 ⁷⁸	ORR	PFS	Various	NR	Targeted	58	2992*			Regression (NR) (ORR vs. med PFS)	R2=0.61, p<0.0001	
Vidaurre 2009 ⁷⁸	ORR	PFS	Various	NR	Chemo or targeted	143 [†]	6974 [†]			Regression (NR) (ORR vs. med PFS)	R2=0.56, p<0.0001	
ORR vs. OS												
Agarwal 2017 ²⁰	ORR	OS	Acute myeloid leukemia	1st	Systemic	20 [†]	NR			WLR adj R2 (logit ORR vs. log med OS)	Adj R2=0.45, p=NR	
Liu 2016 ⁵¹	ORR	OS	Breast	2nd + 3rd	Chemo	24	8617	Spearman (ORR vs. med OS)	rs=0.54 (0.29 to 0.72), p<0.0001			
Liu 2016 ⁵¹	ORR	OS	Breast	- 2nd + 3rd - Previous anthracycline/taxanes	Chemo	15*	NR	Spearman (ORR vs. med OS)	rs=0.62 (0.32 to 0.84), p=NR			
Liu 2016 ⁵¹	ORR	OS	Breast	- 2nd + 3rd - Previous trastuzumab/bvacicizumab	Chemo	5*	NR	Spearman (ORR vs. med OS)	rs=0.78 (0.19 to 1.0), p=NR			
Liu 2016 ⁵¹	ORR	OS	Breast	2nd + 3rd	Chemo (taxanes)	21*	NR	Spearman (ORR vs. med OS)	rs=0.49 (-0.19 to 0.92), p=NR			
Liu 2016 ⁵¹	ORR	OS	Breast	2nd + 3rd	Chemo (antimetabolites)	22*	NR	Spearman (ORR vs. med OS)	rs=-0.10, p=NR			
Liu 2016 ⁵¹	ORR	OS	Breast	- 2nd + 3rd - HER2-pos	Chemo	5*	NR	Spearman (ORR vs. med OS)	rs=0.96 (0.80 to 1.00), p=NR			
Liu 2016 ⁵¹	ORR	OS	Breast	- 2nd + 3rd - HER2-neg	Chemo	3*	NR	Spearman (ORR vs. med OS)	rs=1.00, p=NR			
Petrelli 2014 ⁶⁴	ORR	OS	Breast	1st	Targeted + chemo	20 [†]	10138 [†]	Spearman, wtd (ORR vs. med OS)	rs=0.61 (0.59 to 0.63), p=NR			
Giessen 2015 ³⁵	ORR	OS	Colorectal	2nd	Chemo	22	10509	Pearson, wtd (log odds ORR vs. log med OS)	r=0.58 (0.38 to 0.72), p=0.003			
Louvet 2001 ⁵²	ORR	OS	Colorectal	1st	Various	28*	13284*	Spearman (ORR vs. med OS)	rs=0.41, p=0.0009	LR (ORR vs. med OS)		OS = 10.45 + 0.088 * ORR

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
Tang 2007 ⁷⁵	ORR	OS	Colorectal	1st	Chemo	39	18668	Spearman (ORR vs. med OS)	rs=0.59 (0.42 to 0.72), p<0.000001			
Ichikawa 2006 ⁴²	ORR	OS	Gastric	1st	Chemo (any)	25	4593	Spearman, wtd (ORR vs. med OS)	rs=0.45, p<0.0001	WLR (ORR vs. med OS)		OS = 5.89 + 0.08 * ORR
Ichikawa 2006 ⁴²	ORR	OS	Gastric	1st	Chemo (novel)	11*	1170	Spearman, wtd (ORR vs. med OS)	rs=0.18, p=0.12			
Ichikawa 2006 ⁴²	ORR	OS	Gastric	1st	Chemo (non-novel)	20*	3423	Spearman, wtd (ORR vs. med OS)	rs=0.47, p<0.0001			
Shitara 2014 ⁷⁰	ORR	OS	Gastric	2nd + 3rd	Chemo	64	4286	Spearman (ORR vs. med OS)	rs=0.38 (0.16 to 0.6), p=NR			
Pang 2018 ⁶¹	ORR	OS	Gastroesophageal	1st + 2nd	Targeted	18	7892	Correlation (NR) (ORR vs. med OS)	r=0.86, p<0.0001			
Han 2014 ³⁸	ORR	OS	Glioblastoma	Various	Various	91 [†]	7125 [†]			WLR R2 (ORR vs. med OS)	R2=0.22 (0.04 to 0.42), p=NR	
Ito 2019 ⁴⁵	ORR	OS	Lung (NSCLC)	Various	Immune checkpoint inhibitors (PD-(L)1)	6	3752 [†]	a) Pearson, wtd b) Spearman, wtd (ORR vs. med OS)	a) r= -0.02, p=0.4564 b) rs= -0.14, p<0.0001			
Ito 2019 ⁴⁵	ORR	OS	Lung (NSCLC)	- Various - High PD-L1 expression	Immune checkpoint inhibitors (PD-(L)1)	7	1381	a) Pearson, wtd b) Spearman, wtd (ORR vs. med OS)	a) r=0.92, p<0.0001 b) rs=0.77, p<0.0001	WLR R2 (ORR vs. med OS)	R2=0.84, p=0.004	
Li 2019 ⁴⁹	ORR	OS	Lung (NSCLC)	1st + 2nd	Immune checkpoint inhibitors	5 [†]	4803 [†]	Pearson (ORR vs. med OS)	r=0.52, p=0.28	LR (ORR vs. med OS)	R2=0.27, p=NR	
Li 2012 ⁵⁰	ORR	OS	Lung (NSCLC)	1st + 2nd	Targeted	60	9903			WLSR R2 (ORR vs. med OS)	R2=0.83, p<0.000001	
Ritchie 2018 ⁶⁵	ORR	OS	Lung (NSCLC)	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	8	NR	Correlation (NR) (ORR vs. 12mo OS)	r=0.66 (0.17 to 1.08), p=NR			
Sekine 1999 ⁶⁸	ORR	OS	Lung (NSCLC)	Various	Chemo	42	1935	Pearson (ORR vs. med OS)	r=0.62, p<0.001			
Shukuya 2016 ⁷¹	ORR	OS	Lung (NSCLC)	All	Immune checkpoint inhibitors (PD-(L)1)	10 [†]	NR	Spearman, wtd (ORR vs. med OS)	rs=0.45, p=0.141			
Shukuya 2016 ⁷¹	ORR	OS	Lung (NSCLC)	All	Chemo (docetaxel)	22 [†]	NR	Spearman, wtd (ORR vs. med OS)	rs=0.41, p=0.053			

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
Tsujino 2009 ⁷⁶	ORR	OS	Lung (NSCLC)	NR	Targeted	28	6171			LR (ORR vs. med OS)	R2=NR, p<0.0001	Slope 0.258
Vidaurre 2009 ⁷⁸	ORR	OS	Lung (NSCLC)	NR	Chemo or targeted	35	NR			Regression (NR) (ORR vs. med OS)	R2=0.28, p=0.0024	
Nickolich 2014 ⁵⁹	ORR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited or extensive	Various	66 [†]	8471 [†]	Pearson (ORR vs. med OS)	r=0.66, p<0.0001			
Nickolich 2014 ⁵⁹	ORR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited disease	Various	66 [†]	8471 [†]	Pearson (ORR vs. med OS)	r=0.40, p=0.193			
Nickolich 2014 ⁵⁹	ORR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Extensive disease	Various	66 [†]	8471 [†]	Pearson (ORR vs. med OS)	r=0.44, p=0.012			
Imaoka 2017 ⁴³	ORR	OS	Neuroendocrine	Various	Systemic	20	2530	Spearman (ORR vs. med OS)	rs= -0.26 (-0.64 to 0.11), p=0.164			
Rose 2010 ⁶⁶	ORR	OS	Ovarian	2nd	Various	11	407	a) Pearson b) Kendall Tau-b (ORR vs. med OS)	a) r=0.56, p=0.071 b) r=0.40, p=0.086			
Siddiqui 2017 ⁷²	ORR	OS	Ovarian	2nd +	Chemo	31 [†]	9223 [†]	a) Pearson, wtd (ORR vs. med OS) b) Pearson, unwd (ORR vs. med OS)	a) r=0.82, p<0.001 b) 0.71, p<0.001	WLR R2 (ORR vs. med OS): a) unadj b) adj	a) R2=0.67, p=NR b) adj R2=0.66, p=NR	med OS = 9.48 + 0.28 * ORR
Hamada 2016 ³⁷	ORR	OS	Pancreatic	1st	Chemo	47	15906 [†]	Spearman (ORR vs. med OS)	rs=0.39 (0.20 to 0.55), p<0.001			
Abdel-Rahman 2018 ¹⁸	ORR	OS	Renal cell	Various	Immune checkpoint inhibitors (PD-(L)1)	4	1093	Pearson (ORR vs. med OS)	r= -0.40, p=0.436			
Petrelli 2013 ⁶³	ORR	OS	Renal cell	1st	Targeted	6 [†]	3188 [†]	Spearman, wtd (ORR vs. med OS)	rs=0.96, p<0.0001			
Penel 2014 ⁶²	ORR	OS	Unknown primary	NR	NR	38 [†]	NR	Pearson via WLR (ORR v. med OS)	r=0.54, p<0.0001			

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
Abdel-Rahman 2018 ¹⁸	ORR	OS	Urothelial	Various	Immune checkpoint inhibitors (PD-(L)1)	9	1699	Pearson (ORR vs. med OS)	r= -0.12, p=0.758			
Agarwal 2014 ¹⁹	ORR	OS	Urothelial	2nd	Chemo or biologic	10	560	Pearson (ORR vs. 12mo OS)	r=0.37, p=0.30	WLR R2 (ORR vs. 12mo OS): a) unadj b) adj (RE)	a) R2=0.26, p=NR b) Adj R2=0.16, p=0.1359	
Agarwal 2014 ¹⁹	ORR	OS	Urothelial	- 2nd - Operable	Chemo	NR	214 [†]	Pearson (ORR vs. 12mo OS)	r=0.78, p=NR	WLR adj R2 (ORR vs. 12mo OS)	Adj R2=0.54, p=NR	
Agarwal 2014 ¹⁹	ORR	OS	Urothelial	- 2nd - Metastatic	Chemo	NR	391 [†]	Pearson (ORR vs. 12mo OS)	r= -0.018, p=NR	WLR adj R2 (ORR vs. 12mo OS)	Adj R2= -0.13, p=NR	
Nie 2019 ⁶⁰	ORR	OS	Various solid tumours	Various	Immune checkpoint inhibitors (PD-(L)1)	43 [†]	15088 [†]			Squared Spearman (ORR vs. med OS)	r2s=0.29, p<0.001	
Ritchie 2018 ⁶⁵	ORR	OS	Various solid tumours	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	20 [†]	10828 [†]	Correlation (NR) (ORR vs. 12mo OS)	r=0.08 (-0.17 to 0.70), p=NR			
Vidaurre 2009 ⁷⁸	ORR	OS	Various	NR	Chemo	85	3982*			Regression (NR) (ORR vs. med OS)	R2=0.35, p<0.0001	
Vidaurre 2009 ⁷⁸	ORR	OS	Various	NR	Targeted	58	2992*			Regression (NR) (ORR vs. med OS)	R2=0.45, p<0.0001	
Vidaurre 2009 ⁷⁸	ORR	OS	Various	NR	Chemo or targeted	143 [†]	6794 [†]			Regression (NR) (ORR vs. med OS)	R2=0.33, p<0.0001	
CR vs. PFS												
Nickolich 2014 ⁵⁹	CR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited or extensive	Various	66 [†]	8471 [†]	Pearson (CR vs. med PFS)	r=0.71, p<0.0001			
Nickolich 2014 ⁵⁹	CR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited disease	Various	66 [†]	8471 [†]	Pearson (CR vs. med PFS)	r=0.22, p=0.491			

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
Nickolich 2014 ⁵⁹	CR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Extensive disease	Various	66 [†]	8471 [†]	Pearson (CR vs. med PFS)	r=0.35, p=0.116			
Mangal 2018 ⁵⁵ (myeloma)	CR	PFS	Multiple myeloma	2nd +	Various	79 [†]	13322 [†]			WLR adj R2 (logit CR vs. log med PFS)	Adj R2=0.47, p=NR	
Mangal 2018 ⁵⁴ (NHL)	CR	PFS	NHL	Various	Various	73	6071			LR adj R2 (logit CR vs. log med PFS)	Adj R2=0.57, p=NR	log (med PFS) = 2.38 + 0.340 * logit (CR)
Zhu 2017 ⁸¹	CR	PFS	NHL (indolent; follicular)	NR	Chemo, immune or targeted	13	NR			WLR R2: a) CR vs. med PFS b) CR vs. 3-year PFS	a) R2=0.69 (0.22 to 0.89), p=NR b) R2=0.44, p=NR	med PFS = 0.83 + 0.46 * CR
Zhu 2017 ⁸¹	CR	PFS	NHL (mantle cell)	NR	Chemo, immune or targeted	NR	NR			WLR R2 (CR vs. med PFS)	R2=0.39, p=NR	
CR vs. OS												
Agarwal 2017 ²⁰	CR	OS	Acute myeloid leukemia	1st	Systemic	20 [†]	NR			WLR adj R2 (logit CR vs. log med OS)	Adj R2=0.48, p=NR	
Pang 2018 ⁶¹	CR	OS	Gastroesophageal	1st + 2nd	Targeted	18	7892	Correlation (NR) (CR vs. med OS)	r=0.43, p=0.18			
Li 2019 ⁴⁹	CR	OS	Lung (NSCLC)	1st + 2nd	Immune checkpoint inhibitors	5*	4103*	Pearson (CR vs. med OS)	r=0.19, p=0.75	LR (CR vs. med OS)	R2=0.04, p=NR	
Nickolich 2014 ⁵⁹	CR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited or extensive	Various	66 [†]	8471 [†]	Pearson (CR vs. med OS)	r=0.62, p<0.0001			
Nickolich 2014 ⁵⁹	CR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited disease	Various	66 [†]	8471 [†]	Pearson (CR vs. med OS)	r=-0.04, p=0.863			
Nickolich 2014 ⁵⁹	CR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Extensive disease	Various	66 [†]	8471 [†]	Pearson (CR vs. med OS)	r=0.19, p=0.295			

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Absolute correlation methods	Correlation coefficient (95% CI), p-value	Absolute regression Methods	Regression R2 (95% CI), p-value	Linear regression equation
PR (or VGPR or CR) vs. PFS												
Nickolich 2014 ⁵⁹	PR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited or extensive	Various	66 [†]	8471 [†]	Pearson (PR vs. med PFS)	r=0.35, p=0.019			
Nickolich 2014 ⁵⁹	PR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited disease	Various	66 [†]	8471 [†]	Pearson (PR vs. med PFS)	r=0.70, p=0.011			
Nickolich 2014 ⁵⁹	PR	PFS	Lung (SCLC)	- 1st + 2nd + maintenance - Extensive disease	Various	66 [†]	8471 [†]	Pearson (PR vs. med PFS)	r=0.49, p=0.035			
Mangal 2018 ⁵⁵ (myeloma)	VGPR or CR	PFS	Multiple myeloma	2nd +	Various	79 [†]	13322 [†]			WLR adj R2 (VGPR or CR vs. med PFS)	Adj R2=0.64, p=NR	
PR vs. OS												
Nickolich 2014 ⁵⁹	PR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited or extensive	Various	66 [†]	8471 [†]	Pearson (PR vs. med OS)	r=0.29, p=0.018			
Nickolich 2014 ⁵⁹	PR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Limited disease	Various	66 [†]	8471 [†]	Pearson (PR vs. med OS)	r=0.60, p=0.009			
Nickolich 2014 ⁵⁹	PR	OS	Lung (SCLC)	- 1st + 2nd + maintenance - Extensive disease	Various	66 [†]	8471 [†]	Pearson (PR vs. med OS)	r=0.66, p=0.0002			
*Calculated from reported data. †Unclear for individual subgroups.												
adj, adjusted; chemo, chemotherapy; CI, confidence interval; CR, complete response; FO, final outcome; HER2, human epidermal growth factor receptor 2; log, logarithm; LR, linear regression; med, median; mo, months; NHL, non-Hodgkin's lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; ORR, overall response rate (ORR=PR+CR); OS, overall survival; PFS, progression-free survival; PR, partial response; r, Pearson correlation; R2, regression coefficient of determination; r2s, squared Spearman rank correlation; rs, Spearman rank correlation; SCLC, small cell lung cancer; SO, surrogate outcome; TTP, time to progression; unwt, unweighted; VGPR, very good partial response; wtd, weighted; WLR, weighted linear regression; WLSR, weighted least squares regression.												

11 Supplementary Table 8: Treatment effect correlation and regression results per study

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
ORR vs. PFS															
Burzykowski 2008 ²⁴	ORR	PFS	Breast	1st	Chemo	11	3953	Spearman via LR with Plackett copula (logOR ORR vs. logHR PFS)	rs=0.96 (0.73 to 1.19), p=NR	LR		logHR PFS = 0.10 + 0.50 * logOR ORR	NR	Medium+	NE
Ciani 2015 ²⁶ Elia 2018 ³³	ORR	PFS	Colorectal	All	Systemic	33	NR			LR: Adj R2 (logOR ORR vs. logHR PFS)	Adj R2=0.61 (0.27 to 0.87), p=NR	logHR PFS = -0.05 - 0.32 * logOR ORR	NR	Medium	NE
Ciani 2015 ²⁶ Elia 2018 ³³	ORR	PFS	Colorectal	- All - No crossover	Systemic	7	NR			LR: Adj R2 (logOR ORR vs. logHR PFS)	Adj R2=0.63 (0.03 to 0.99), p=NR	logHR PFS = -0.05 - 0.31 * logOR ORR	NR	Medium	NE
Tsujino 2010 ⁷⁷	ORR	PFS	Colorectal	NR	Targeted	7	NR			LR (unwtd) R2 (diff ORR vs. HR PFS)	R2=0.65, p=0.029	Slope -0.037	NR	Medium	NE
Blumenthal 2017 ²²	ORR	PFS	Lung (NSCLC)	Various	Chemo, immune or targeted	25	20013 [†]			WLR R2: a) OR ORR vs. HR PFS b) 6mo ratio ORR vs. HR PFS	a) R2=0.74 (0.55 to 0.88), p=NR b) R2=0.70 (0.50 to 0.84), p=NR		NR	Medium+	NE
Blumenthal 2015 ²¹	ORR	PFS	Lung (NSCLC)	Various	Chemo or targeted	14	12567 [†]			WLR R2 (logOR ORR vs. logHR PFS)	R2=0.89 (0.80 to 0.98), p=NR		NR	Medium+	NE
Blumenthal 2015 ²¹	ORR	PFS	Lung (NSCLC)	Various	Chemo	11	11701 [†]			WLR R2 (logOR ORR vs. logHR PFS)	R2=0.77 (0.58 to 0.96), p=NR		NR	Medium+	NE
Ito 2019 ⁴⁵	ORR	PFS	Lung (NSCLC)	Various	Immune (PD-(L)1)	6	3752 [†]	a) Pearson, wtd b) Spearman, wtd (OR ORR vs. HR PFS)	a) r= -0.87, p<0.0001 b) rs= -0.97, p<0.0001	WLR R2 (OR ORR vs. HR PFS)	R2=0.76, p=0.011		NR	Medium+	Fair
Ito 2019 ⁴⁵	ORR	PFS	Lung (NSCLC)	- Various - High PD-L1 expression	Immune checkpoint inhibitors (PD-(L)1)	7	1381	a) Pearson, wtd b) Spearman, wtd (OR ORR vs. HR PFS)	a) r=0.67, p<0.0001 b) rs=0.56, p<0.0001	WLR R2 (OR ORR vs. HR PFS)	R2=0.45, p=0.101		NR	Low	Good
Ritchie 2018 ⁶⁵	ORR	PFS	Lung (NSCLC)	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	8	NR	Correlation (NR), wtd (OR ORR vs. HR PFS)	r=0.74 (0.38 to 1.08), p=NR				NR	Medium	Good

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Roviello 2017 ⁶⁷	ORR	PFS	Lung (NSCLC)	Various	Immune checkpoint inhibitors	7*	3369*			WLR R2 (logOR ORR vs. logHR PFS)	R2=0.42 (0.003 to 0.85), p=0.06		NR	Low	NE
Tsujino 2010 ⁷⁷	ORR	PFS	Lung (NSCLC)	NR	Targeted	6	NR			LR (unwtd) R2 (diff ORR vs. HR PFS)	R2=0.94, p=0.002	Slope -0.015	NR	Medium+	NE
Colloca & Venturino 2017 ²⁷	ORR	PFS	Ovarian	1st	Chemo	29	NR	Spearman (diff ORR vs. diff med PFS)	rs=0.64, p<0.001	LR R2 (log RR ORR vs. log HR PFS)	R2=0.28, p=0.005		NR	Low	NE
Colloca & Venturino 2017 ²⁷	ORR	PFS	Ovarian	- 1st - Published 1990-2002	Chemo	15	NR	Spearman (diff ORR vs. diff med PFS)	rs=0.64, p=0.018	LR R2 (log RR ORR vs. log HR PFS)	R2=0.32, p=0.046		NR	Low	NE
Colloca & Venturino 2017 ²⁷	ORR	PFS	Ovarian	- 1st - Published 2003-2016	Chemo	16	NR	Spearman (diff ORR vs. diff med PFS)	rs=0.58, p=0.019	LR R2 (log RR ORR vs. log HR PFS)	R2=0.53, p=0.003		NR	Medium	NE
Siddiqui 2017 ⁷²	ORR	PFS	Ovarian	2nd +	Chemo	39 [†]	9223 [†]	Pearson, wtd (OR ORR vs. HR PFS)	r=0.42, p=NR				NR	Low	Poor
Colloca 2016a ²⁸	ORR	PFS	Pancreatic	1st	Gemcitabine + chemo or targeted	33*	NR	Spearman (diff ORR vs. diff med PFS)	rs=0.34, p=NR				NR	Low	NE
Colloca 2016a ²⁸	ORR	PFS	Pancreatic	1st	Gemcitabine + targeted	14*	NR	Spearman (diff ORR vs. diff med PFS)	rs=0.25, p=NR				NR	Low	NE
Ritchie 2018 ⁶⁵	ORR	PFS	Various solid tumours	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	20 [†]	10828 [†]	Correlation (NR), wtd (OR ORR vs. HR PFS)	r=0.63 (0.35 to 0.89), p=NR				NR	Medium	Poor
Roviello 2017 ⁶⁷	ORR	PFS	Various solid tumours	Various	Immune checkpoint inhibitors	17 [†]	8994 [†]			WLR R2 (logOR ORR vs. logHR PFS)	R2=0.32 (0.02 to 0.76), p=0.01	logHR PFS = -0.1281 - 0.2384 * logOR ORR	NR	Low	NE
Roviello 2017 ⁶⁷	ORR	PFS	Various solid tumours	Various	Immune checkpoint inhibitors (CTLA-4)	17 [†]	8994 [†]			WLR R2 (logOR ORR vs. logHR PFS)	R2=0.67 (0.02 to 1.00), p=0.05		NR	Medium	NE
Roviello 2017 ⁶⁷	ORR	PFS	Various solid tumours	Various	Immune checkpoint inhibitors (PD-(L)1)	17 [†]	8994 [†]			WLR R2 (logOR ORR vs. logHR PFS)	R2=0.25 (0.02 to 1.00), p=0.08		NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Tsujino 2010 ⁷⁷	ORR	PFS	Various solid tumours	NR	Targeted	17	NR			LR (unwtd) R2 (diff ORR vs. HR PFS)	R2=0.50, p=0.001	Slope -0.022	15%	Medium	NE
Wilkerson+ Fojo 2009 ⁷⁹	ORR	PFS	Various solid tumours	NR	NR	66 [†]	NR			LR (unwtd R2): a) diff ORR vs. HR PFS b) diff ORR vs. diff med PFS	a) R2=0.45, p<0.0001 b) R2=0.62, p<0.0001		NR	Medium	NE
ORR vs. OS															
Moriwaki 2016 ⁵⁶	ORR	OS	Biliary tract	1st	Chemo	17 [†]	2040			WLR R2 (ratio ORR vs. log ratio med OS)	R2=0.29 (0.01 to 0.65), p=0.021	log ratio med OS = 0.013 + 0.282 * ratio ORR	NR	Low	NE
Moriwaki 2016 ⁵⁶	ORR	OS	Biliary tract	1st	Chemo (gemcitabine)	14 [†]	1880			WLR R2 (ratio ORR vs. log ratio med OS)	R2=0.39 (0.02 to 0.75), p=0.013	log ratio med OS = 0.020 + 0.268 * ratio ORR	NR	Low	NE
Moriwaki 2016 ⁵⁶	ORR	OS	Biliary tract	1st	Targeted	6 [†]	953			WLR R2 (ratio ORR vs. log ratio med OS)	R2=0.43 (0.03 to 0.89), p=0.090	log ratio med OS = 0.119 + 0.155 * ratio ORR	NR	Low	NE
Bruzzi 2005 ²³	ORR	OS	Breast	All	Chemo	10	2126			WLR R2: a) logOR ORR vs. logHR OS b) diff ORR vs. diff med OS	a) R2=0.10 (0.00 to 0.43), p=NR b) R2=0.20 (0 to 0.65), p=NR		NR	Low	NE
Burzykowski 2008 ²⁴	ORR	OS	Breast	1st	Chemo	11	3953	Spearman via LR with Plackett copula (logOR ORR vs. logHR OS)	rs=0.57 (-0.31 to 1.44), p=NR				NR	Medium	NE
Hackshaw 2005 ³⁶	ORR	OS	Breast	1st	Chemo	42*	9163			WLR R2 (logOR ORR vs. logHR OS)	R2=0.34, p<0.0001	logHR OS = -0.0081 + 0.28 * logOR ORR Slope 0.28	NR	Low	NE
Hackshaw 2005 ³⁶	ORR	OS	Breast	- 1st - Recruited pre-1990	Chemo	26*	5244*			WLR R2 (logOR ORR vs. logHR OS)	R2=0.26, p=0.004	Slope 0.28	NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Hackshaw 2005 ³⁶	ORR	OS	Breast	- 1st - Recruited 1990 or after	Chemo	16*	3919*			WLR R2 (logOR ORR vs. logHR OS)	R2=0.41, p=0.005	Slope 0.24	NR	Low	NE
Buyse 2000 ²⁵	ORR	OS	Colorectal	1st	Chemo	25	3791			WLR R2 (logOR ORR vs. logHR OS)	R2=0.38 (0.09 to 0.68), p=NR		NR	Low	NE
Ciani 2015 ²⁶ Elia 2018 ³³	ORR	OS	Colorectal	All	Systemic	32	NR	Spearman (logOR ORR vs. logOR OS)	rs=0.53, p<0.01	a) WLSR R2 (logOR ORR vs. logOR OS) (timepoint NR) b) Adj R2 (logOR ORR vs. logHR OS)	a) R2=0.06 (0.01 to 0.29), p=NR b) Adj R2=0.33 (0.00 to 0.91), p=NR	logHR OS = -0.03 - 0.05 * logOR ORR	0.28	Low	NE
Ciani 2015 ²⁶ Elia 2018 ³³	ORR	OS	Colorectal	- All - No crossover	Systemic	7	NR			LR: Adj R2 (logOR ORR vs. logHR OS)	Adj R2=0.40 (0.00 to 0.96), p=NR	logHR OS = -0.04 - 0.10 * logOR ORR	NR	Low	NE
Colloca 2016b ²⁹	ORR	OS	Colorectal	1st	Bevacizumab + chemo	11	NR	Spearman (diff ORR vs. diff med OS)	rs=0.82, p<0.001	LR R2 (diff ORR vs. diff med OS)	R2=0.58, p=0.002		NR	Medium	NE
Cremolini 2017 ³¹	ORR	OS	Colorectal	2nd	Targeted	20*	7571	Pearson (via WLR): a) rr ORR vs. HR OS b) diff ORR vs. diff med OS	a) r=0.17, p=0.476 b) r=0.35, p=0.092	WLR R2: a) rr ORR vs. HR OS b) diff ORR vs. diff med OS	b) R2=0.03, p=0.476 b) R2=0.12, p=0.092	a) Slope -0.029 b) Slope 0.071	NR	Low	NE
Cremolini 2017 ³¹	ORR	OS	Colorectal	2nd	Targeted, anti-angiogenic	13*	NR	Pearson (via WLR): a) rr ORR vs. HR OS b) diff ORR vs. diff med OS	a) r=0.36, p=0.249 b) r=0.52, p=0.038	WLR R2: a) rr ORR vs. HR OS b) diff ORR vs. diff med OS	b) R2=0.13, p=0.249 b) R2=0.27, p=0.038	a) Slope -0.113 b) Slope 0.133	NR	Low	NE
Cremolini 2017 ³¹	ORR	OS	Colorectal	2nd	Targeted, not anti-angiogenic	7*	NR	Pearson (via WLR): a) rr ORR vs. HR OS b) diff ORR vs. diff med OS	a) r=0.44, p=0.274 b) r=0.63, p=0.068	WLR R2: a) rr ORR vs. HR OS b) diff ORR vs. diff med OS	b) R2=0.20, p=0.274 b) R2=0.40, p=0.068	a) Slope -0.064 b) Slope 0.143	NR	Low	NE
Johnson 2006 ⁴⁶	ORR	OS	Colorectal	1st	Chemo	146 [†]	35337 [†]			WLSR R2 (diff ORR vs. diff med OS)	R2=0.10, p<0.0001	Diff med OS = 0.340 + 0.096 * diff ORR	NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Sidhu 2013 ⁷³	ORR	OS	Colorectal	1st (most)	Chemo +/- targeted	24 [†]	20438 [†]	Correlation (NR): a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) r=0.62 (0.37 to 0.79), p=NR b) r=0.64 (0.39 to 0.79), p=NR c) r=0.52 (0.23 to 0.72), p=NR	LR (unwtd) R2: a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) R2=0.39 (0.13 to 0.62), p=NR b) R2=0.41 (0.15 to 0.63), p=NR c) R2=0.27 (0.05 to 0.52), p=NR		NR	Medium	NE
Sidhu 2013 ⁷³	ORR	OS	Colorectal	1st (most)	Targeted + chemo	13	12060*	Correlation (NR): a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) r=0.50 (0.05 to 0.75), p=NR b) r=0.58 (0.19 to 0.80), p=NR c) r=0.42 (0.00 to 0.71), p=NR	LR (unwtd) R2: a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) R2=0.25 (0.00 to 0.57), p=NR b) R2=0.33 (0.04 to 0.64), p=NR c) R2=0.18 (0.00 to 0.51), p=NR		NR	Medium	NE
Sidhu 2013 ⁷³	ORR	OS	Colorectal	1st (most)	Targeted (anti-EGFR)	9	7792*	Correlation (NR): a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) r=0.67 (0.27 to 0.86), p=NR b) r=0.72 (0.35 to 0.88), p=NR c) r=0.52 (0.00 to 0.79), p=NR	LR (unwtd) R2: a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) R2=0.45 (0.07 to 0.74), p=NR b) R2=0.52 (0.12 to 0.78), p=NR c) R2=0.27 (0.00 to 0.62), p=NR		NR	Medium	NE
Sidhu 2013 ⁷³	ORR	OS	Colorectal	1st (most)	Targeted (anti-EGFR), KRAS non-mutant	6*	4916*	Correlation (NR): a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) r=0.68 (0.07 to 0.89), p=NR b) r=0.81 (0.38 to 0.94), p=NR c) r=0.48 (0.00 to 0.82), p=NR	LR (unwtd) R2: a) OR ORR vs. HR OS b) Diff ORR vs. HR OS c) Ratio ORR vs. HR OS	a) R2=0.46 (0.01 to 0.80), p=NR b) R2=0.65 (0.15 to 0.88), p=NR c) R2=0.23 (0.00 to 0.67), p=NR		NR	Medium	NE
Tang 2007 ⁷⁵	ORR	OS	Colorectal	1st	Chemo	39	18668	Spearman (diff ORR vs. diff med OS)	rs=0.39 (0.08 to 0.63), p=0.015				NR	Low	Poor
Tsujino 2010 ⁷⁷	ORR	OS	Colorectal	NR	Targeted	7	NR			LR (unwtd) R2 (diff ORR vs. HR OS)	R2=0.51, p=0.072	Slope -0.029	NR	Medium	NE
Blumenthal 2017 ²²	ORR	OS	Lung (NSCLC)	Various	Chemo, immune or targeted	25	20013 [†]			WLR R2: a) OR ORR vs. HR OS b) 6mo ratio ORR vs. HR OS	a) R2=0.04 (0.0002 to 0.28), p=NR b) R2=0.05 (0.0001 to 0.31), p=NR		NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Blumenthal 2015 ²¹	ORR	OS	Lung (NSCLC)	Various	Chemo or targeted	14	12567 [†]			WLR R2 (logOR ORR vs. logHR OS)	R2=0.09 (0 to 0.33), p=NR		NR	Low	NE
Blumenthal 2015 ²¹	ORR	OS	Lung (NSCLC)	Various	Chemo	11	11701 [†]			WLR R2 (logOR ORR vs. logHR OS)	R2=0.44 (0.08 to 0.80), p=NR		NR	Low	NE
Hashim 2018 ³⁹	ORR	OS	Lung (NSCLC)	2nd +	Various	140	41725	Correlation (NR) via WLR: a) diff ORR vs. logHR OS b) diff ORR vs. diff med OS	a) r=0.17 (0.00 to 0.38), p=NR b) r=0.18 (0.02 to 0.34), p=0.032				NA	Low	NE
Hashim 2018 ³⁹	ORR	OS	Lung (NSCLC)	- 2nd + - Phase III	Various	59	32348	Correlation (NR) via WLR: a) diff ORR vs. logHR OS b) diff ORR vs. diff med OS	a) r=0.37 (0.09 to 0.60), p=NR b) r=0.13 (0.00 to 0.38), p=0.32				NA	Low	NE
Hashim 2018 ³⁹	ORR	OS	Lung (NSCLC)	- 2nd + - Phase III excl per-protocol crossover	Various	54	30654	Correlation (NR) via WLR: a) diff ORR vs. logHR OS b) diff ORR vs. diff med OS	a) r=0.40 (0.10 to 0.63), p=NR b) r=0.36 (0.10 to 0.57), p=0.0074				NA	Low	NE
Hashim 2018 ³⁹	ORR	OS	Lung (NSCLC)	- 2nd + - Phase III excl any crossover	Various	38	22574	Correlation (NR) via WLR: a) diff ORR vs. logHR OS b) diff ORR vs. diff med OS	a) r=0.52 (0.18 to 0.75), p=NR b) r=0.45 (0.15 to 0.67), p=0.0051				a) 55% b) NA	Medium	NE
Hashim 2018 ³⁹	ORR	OS	Lung (NSCLC)	- 2nd + - Phase III excl crossover or unbalanced post-progression treatments	Various	18	13349	Correlation (NR) via WLR: a) diff ORR vs. logHR OS b) diff ORR vs. diff med OS	a) r=0.16 (0.00 to 0.60), p=NR b) r=0.53 (0.08 to 0.80), p=0.024				a) NA b) 41%	Low	NE
Hotta 2015 ⁴⁰	ORR	OS	Lung (NSCLC)	Various	Targeted	18	7633 [†]			WLR R2 (OR ORR vs. HR OS)	R2=0.10, p=NR		NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Hotta 2015 ⁴⁰	ORR	OS	Lung (NSCLC)	- Various - Molecularly selected	Targeted	8	NR			WLR R2 (OR ORR vs. HR OS)	R2=0.04, p=NR		NR	Low	NE
Hotta 2015 ⁴⁰	ORR	OS	Lung (NSCLC)	- Various - Non-molecularly selected	Targeted	10	NR			WLR R2 (OR ORR vs. HR OS)	R2=0.43, p=NR		NR	Low	NE
Ito 2019 ⁴⁵	ORR	OS	Lung (NSCLC)	Various	Immune checkpoint inhibitors (PD-(L)1)	6	3752 [†]	a) Pearson, wtd b) Spearman, wtd (OR ORR vs. HR OS)	a) r= -0.75, p<0.0001 b) rs= -0.96, p<0.0001	WLR R2 (OR ORR vs. HR OS)	R2=0.57, p=0.051		NR	Medium	Poor
Ito 2019 ⁴⁵	ORR	OS	Lung (NSCLC)	- Various - High PD-L1 expression	Immune checkpoint inhibitors (PD-(L)1)	7	1381	a) Pearson, wtd b) Spearman, wtd (OR ORR vs. HR OS)	a) r= -0.50, p<0.0001 b) rs= -0.21, p<0.0001	WLR R2 (OR ORR vs. HR OS)	R2=0.25, p=0.253		NR	Low	Fair
Johnson 2006 ⁴⁶	ORR	OS	Lung (NSCLC)	1st	Chemo	191 [†]	44125 [†]			WLSR R2 (diff ORR vs. diff med OS)	R2=0.16, p<0.0001	Diff med OS = -0.048 + 0.090 * diff ORR	NR	Low	NE
Nakashima 2016 ⁵⁸	ORR	OS	Lung (NSCLC)	1st	Chemo	44	22709	Spearman, wtd (lnOR ORR vs. HR OS)	rs=0.57, p=NR	WLSR adj R2 (lnOR ORR vs. lnHR OS)	Adj R2=0.35, p=NR	lnHR OS = -0.023 -0.133 x lnOR ORR	NR	Low	NE
Ritchie 2018 ⁶⁵	ORR	OS	Lung (NSCLC)	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	8	NR	Correlation (NR), wtd (OR ORR vs. HR OS)	r=0.68 (0.08 to 1.10), p=NR				NR	Low	Good
Roviello 2017 ⁶⁷	ORR	OS	Lung (NSCLC)	Various	Immune checkpoint inhibitors	7*	3369*			WLR R2 (logOR ORR vs. logHR OS)	R2=0.0007 (0.09 to 0.91), p=0.94		NR	Low	NE
Tsujino 2010 ⁷⁷	ORR	OS	Lung (NSCLC)	NR	Targeted	5	NR			LR (unwtd) R2 (diff ORR vs. HR OS)	R2=0.84, p=0.030	Slope -0.011	NR	Medium+	NE
Foster 2011 ³⁴	ORR	OS	Lung (SCLC)	1st	Chemo	3 (32 centres)	596 [†]	Spearman (logOR ORR vs. logHR OS)	rs=0.52, p=NR	WLSR R2 (logOR ORR vs. logHR OS)	R2=0.21, p=NR		NR	Low	NE
Hotta 2009 ⁴¹	ORR	OS	Lung (SCLC)	1st	Chemo	48	8779			WLR R2 (rr ORR vs. diff med OS)	R2=0.33, p=NR	Diff med OS = 0.00 + 0.06 * rr ORR	NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Hotta 2009 ⁴¹	ORR	OS	Lung (SCLC)	- 1st - Clear criteria	Chemo	43 comp	NR			WLR R2 (rr ORR vs. diff med OS)	R2=0.19, p=NR		NR	Low	NE
Hotta 2009 ⁴¹	ORR	OS	Lung (SCLC)	- 1st - WHO criteria	Chemo	23 comp	NR			WLR R2 (rr ORR vs. diff med OS)	R2=0.13, p=NR		NR	Low	NE
Hotta 2009 ⁴¹	ORR	OS	Lung (SCLC)	- 1st - Non-WHO criteria	Chemo	20 comp	NR			WLR R2 (rr ORR vs. diff med OS)	R2=0.28, p=NR		NR	Low	NE
Hotta 2009 ⁴¹	ORR	OS	Lung (SCLC)	- 1st - Published 1990-1996	Chemo	26 comp	NR			WLR R2 (rr ORR vs. diff med OS)	R2=0.23, p=NR	Diff med OS = 0.00 + 0.04 * rr ORR	NR	Low	NE
Hotta 2009 ⁴¹	ORR	OS	Lung (SCLC)	- 1st - Published 1997-2008	Chemo	26 comp	NR			WLR R2 (rr ORR vs. diff med OS)	R2=0.47, p=NR	Diff med OS = 0.00 + 0.09 * rr ORR	NR	Low	NE
Colloca & Venturino 2017 ²⁷	ORR	OS	Ovarian	1st	Chemo	27	NR	Spearman (diff ORR vs. diff med OS)	rs=0.41, p=0.035	LR R2 (log RR ORR vs. log HR OS)	R2=0.12, p=0.073		NR	Low	NE
Colloca & Venturino 2017 ²⁷	ORR	OS	Ovarian	- 1st - Published 1990-2002	Chemo	13	NR	Spearman (diff ORR vs. diff med OS)	rs=0.65, p=0.016	LR R2 (log RR ORR vs. log HR OS)	R2=0.15, p=0.199		NR	Low	NE
Colloca & Venturino 2017 ²⁷	ORR	OS	Ovarian	- 1st - Published 2003-2016	Chemo	14	NR	Spearman (diff ORR vs. diff med OS)	rs= -0.02, p=0.940	LR R2 (log RR ORR vs. log HR OS)	R2=0.34, p=0.027		NR	Low	NE
Siddiqui 2017 ⁷²	ORR	OS	Ovarian	2nd +	Chemo	31 [†]	9223 [†]						NR	NE	NE
Colloca 2016a ²⁸	ORR	OS	Pancreatic	1st	Gemcitabine + chemo or targeted	36*	NR	Spearman (diff ORR vs. diff med OS)	rs=0.29, p=0.067				NR	Low	NE
Colloca 2016a ²⁸	ORR	OS	Pancreatic	1st	Gemcitabine + chemo	22*	NR	Spearman (diff ORR vs. diff med OS)	rs=0.23, p=0.250	LR R2 (logRR ORR vs. logHR OS)	R2=0.15, p=NR		NR	Low	NE
Colloca 2016a ²⁸	ORR	OS	Pancreatic	1st	Gemcitabine + targeted	14*	NR	Spearman (diff ORR vs. diff med OS)	rs=0.55, p=0.035	LR R2 (logRR ORR vs. logHR OS)	R2=0.28, p=NR		NR	Low	NE
Hamada 2016 ³⁷	ORR	OS	Pancreatic	1st	Chemo	36	15906 [†]	Spearman via WLSR (logOR ORR vs. logHR OS)	rs= -0.16 (-0.27 to -0.05), p=0.007	WLSR adj R2 (logOR ORR vs. logHR OS)	Adj R2=0.30, p=0.007		NR	Low	Poor

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Makris 2017 ⁵³	ORR	OS	Pancreatic (adenocarcinoma)	1st	Chemo (gemcitabine)	22*	10379*	Pearson (log HR OS vs. log ORR): a) wtd by sample size b) fixed effect c) random effects	a) r=0.27 (-0.14 to 0.60), p=0.20 b) r=0.52 (0.16 to 0.76), p=0.007 c) r=0.45 (0.07 to 0.72), p=0.02				NR	Low	NE
Makris 2017 ⁵³	ORR	OS	Pancreatic (adenocarcinoma)	- 1 st - No crossover	Chemo (gemcitabine)	22*	10379*	Pearson (log HR OS vs. log ORR): a) wtd by sample size b) fixed effect c) random effects	a) r= -0.10 (-0.56 to 0.40), p=0.70 b) r=0.16 (-0.34 to 0.60), p=0.53 c) r=0.21 (-0.30 to 0.62), p=0.43				NR	Low	NE
Makris 2017 ⁵³	ORR	OS	Pancreatic (adenocarcinoma)	- 1 st - Crossover <50%	Chemo (gemcitabine)	22*	10379*	Pearson (log HR OS vs. log ORR): a) wtd by sample size b) fixed effect c) random effects	a) r=0.26 (-0.18 to 0.62), p=0.24 b) r=0.53 (0.15 to 0.78), p=0.009 c) r=0.45 (0.03 to 0.73), p=0.03				NR	Low	NE
Colloca 2016 ³⁰	ORR	OS	Prostate	1st + 2nd	Chemo, hormonal + targeted	17	NR	Pearson (diff ORR vs. diff med OS)	r=0.38, p=0.132	LR R2 (log RR ORR vs. log HR OS)	R2=0.007, p=0.789		NR	Low	NE
Colloca 2016 ³⁰	ORR	OS	Prostate	- 1st + 2nd - Published 1995-2004	Chemo, hormonal + targeted	5	NR	Pearson (diff ORR vs. diff med OS)	r=0.35, p=0.560	LR R2 (log RR ORR vs. log HR OS)	R2=0.53, p=0.275		NR	Medium	NE
Colloca 2016 ³⁰	ORR	OS	Prostate	- 1st + 2nd - Published 2005-2014	Chemo, hormonal + targeted	12	NR	Pearson (diff ORR vs. diff med OS)	r=0.41, p=0.185	LR R2 (log RR ORR vs. log HR OS)	R2=0.02, p=0.690		NR	Low	NE
Delea 2012 ³²	ORR	OS	Renal cell	NR	Cytokine or targeted	25*	10943 [†]	Pearson, wtd (ln(rr) ORR vs. -lnHR OS)	r=0.78, p<0.0001	WLSR adj R2 (ln rr ORR vs. -lnHR OS)	Adj R2=0.59, p<0.0001	-lnHR OS = -0.11 + 0.30 * lnrr ORR	NR	Medium	NE
Petrelli 2013 ⁶³	ORR	OS	Renal cell	1st	Targeted	6 [†]	3188 [†]	a) Pearson, wtd b) Spearman, wtd (diff med OS vs. diff ORR)	a) r =0.52, p<0.0001 b) rs = 0.49, p<0.0001	LR	R2=0.27, p=NR		NR	Low	Fair
Tanaka 2019 ⁷⁴	ORR	OS	Soft tissue sarcoma	1st	Chemo	27 [†]	6156 [†]	Kendall's Tau (logOR ORR vs. logHR OS)	τ=0.41, p=NR	Regression (NR) R2 (logOR ORR vs. logHR OS)	R2=0.28 (0.02 to 0.54), p=NR		NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Zer 2016 ⁸⁰	ORR	OS	Soft tissue sarcoma	All	Systemic	52 [†]	9762 [†]	Correlation (NR) via WLR (OR ORR vs. HR OS)	r=0.51, p=NR				NR	Low	NE
Kaufman 2018 ⁴⁷	ORR	OS	Various solid tumours	Various	Immune checkpoint inhibitors + chemo	27 [†]	10300 [†]			WLR adj R2 (OR ORR vs. HR OS)	Adj R2= -0.07, p=0.866		NR	NE	NE
Kaufman 2018 ⁴⁷	ORR	OS	Various solid tumours	Various	Immune checkpoint inhibitors alone	NR	NR			WLR adj R2 (OR ORR vs. HR OS)	Adj R2= -0.08, p=0.799		NR	NE	NE
Mushti 2018 ⁵⁷	ORR	OS	Various solid tumours	NR	Immune checkpoint inhibitors (PD-(L)1)	13	6722			WLR R2 (OR ORR vs. HR OS)	R2=0.13, p=NR		NR	Low	NE
Nie 2019 ⁶⁰	ORR	OS	Various solid tumours	Various	Immune checkpoint inhibitors (PD-(L)1)	43 [†]	15088 [†]			WLR R2 (lnOR ORR vs. lnHR OS)	R2=0.10, p=0.053		NR	Low	Poor
Ritchie 2018 ⁶⁵	ORR	OS	Various solid tumours	All	Immune checkpoint inhibitors (PD-(L)1 or CTLA4)	20 [†]	10828 [†]	Correlation (NR), wtd (OR ORR vs. HR OS)	r=0.57 (0.23 to 0.89), p=NR				NR	Low	Poor
Roviello 2017 ⁶⁷	ORR	OS	Various solid tumours	Various	Immune checkpoint inhibitors	17 [†]	8994 [†]			WLR R2 (logOR ORR vs. logHR OS)	R2=0.47 (0.03 to 0.77), p=0.001	logHR OS = -0.1329 - 0.2575 * logOR ORR	NR	Low	NE
Roviello 2017 ⁶⁷	ORR	OS	Various solid tumours	Various	Immune checkpoint inhibitors (CTLA-4)	17 [†]	8994 [†]			WLR R2 (logOR ORR vs. logHR OS)	R2=0.00 (0.00 to 0.97), p=0.96		NR	Low	NE
Roviello 2017 ⁶⁷	ORR	OS	Various solid tumours	Various	Immune checkpoint inhibitors (PD-(L)1)	17 [†]	8994 [†]			WLR R2 (logOR ORR vs. logHR OS)	R2=0.18 (0.00 to 0.97), p=0.17		NR	Low	NE
Tsujino 2010 ⁷⁷	ORR	OS	Various solid tumours	NR	Targeted	18	NR			LR (unwtd) R2 (diff ORR vs. HR OS)	R2=0.47, p=0.002	Slope -0.016	21%	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Wilkerson+ Fojo 2009 ⁷⁹	ORR	OS	Various solid tumours	NR	NR	66 [†]	NR			LR (unwtd R2): a) diff ORR vs. HR OS b) diff ORR vs. diff med OS	a) R2=0.37, p<0.0001 b) R2=0.34, p<0.0001		NR	Low	NE
CR vs. PFS															
Lee 2011 ⁴⁸	CR	PFS	NHL (aggressive)	1st	Chemo	12 [†]	NR	Spearman (diff CR vs. diff 3yr PFS)	rs=0.63 (0.21 to 0.84), p=0.005				NR	Medium	NE
Lee 2011 ⁴⁸	CR	PFS	NHL (indolent)	1st	Chemo	6 [†]	NR	Spearman (diff CR vs. diff 3yr PFS)	rs=0.41 (-0.52 to 0.88), p=0.35				NR	Medium	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	1st	Chemo or immuno (induction or maintenance)	13	3837			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 30mo vs. logHR PFS)	a) R2WLS=0.88 (0.77 to 0.96), p=NR b) R2Copula=0.86 (0.72 to 1.00), p=NR	logHR PFS = -0.093 - 0.636 * logOR CR 30mo	1.56	Medium+	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	1st	Rituximab-based (induction or maintenance)	9	2851			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 30mo vs. logHR PFS)	a) R2WLS=0.85 (0.62 to 0.97), p=NR b) R2Copula=0.80 (0.56 to 1.00), p=NR		NR	Medium+	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	1st	Non-rituximab-based (induction or maintenance)	4	986			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 30mo vs. logHR PFS)	a) R2WLS=0.91 (0.05 to 1.00), p=NR b) R2Copula=0.96 (0.90 to 1.00), p=NR		NR	Medium+	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	1st	Induction	8	2207			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 30mo vs. logHR PFS)	a) R2WLS=0.89 (0.75 to 0.98), p=NR b) R2Copula=0.89 (0.74 to 1.00), p=NR		NR	Medium+	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	1st	Maintenance	5	1630			wtd least squares (reported as R2WLS) and bivariate Plackett copula model (reported as R2copula), CR30 vs PFS	a) R2WLS=0.93 (0.84 to 1.00), p=NR b) R2Copula=0.89 (0.71 to 1.00), p=NR		NR	Medium+	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	- 1st - High FLIPI score	Chemo or immuno (induction or maintenance)	9	1415			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 30mo vs. logHR PFS)	a) R2WLS=0.87 (0.68 to 0.98), p=NR b) R2Copula=0.73 (0.42 to 1.00), p=NR		NR	Medium+	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	- 1st - Low to intermediate FLIPI score	Chemo or immuno (induction or maintenance)	10	1882			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 30mo vs. logHR PFS)	a) R2WLS=0.45 (0.02 to 0.93), p=NR b) R2Copula=0.57 (0.17 to 0.97), p=NR		NR	Low	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	1st	Chemo or immuno (induction or maintenance)	11	2728			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 24mo vs. logHR PFS)	a) R2WLS=0.84 (0.63 to 0.95), p=NR b) R2Copula=0.67 (0.35 to 0.99), p=NR	logHR PFS = 0.043 - 0.726 * logOR CR24mo	NR	Medium+	NE
Shi 2017 ⁶⁹	CR	PFS	NHL (indolent; follicular)	- 1st - Stage IV	Chemo or immuno (induction or maintenance)	NR	2585			a) WLSR R2 b) Bivariate Plackett copula model (logOR CR 30mo vs. logHR PFS)	a) R2WLS=0.92 (0.85 to 0.97), p=NR b) R2Copula=0.94 (0.87 to 1.00), p=NR		NR	Medium+	NE
Colloca & Venturino 2017 ²⁷	CR	PFS	Ovarian	1st	Chemo	12	NR	Spearman (diff RR vs. diff med PFS)	rs=0.19, p=0.555				NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
CR vs. OS															
Hackshaw 2005 ³⁶	CR	OS	Breast	1st	Chemo	41*	9163 [†]			WLR R2 (logOR CR vs. logHR OS)	R2=0.12, p=0.02	logHR OS = -0.0097 + 0.13 * logOR CR Slope 0.13	NR	Low	NE
Hackshaw 2005 ³⁶	CR	OS	Breast	- 1st - Recruited pre-1990	Chemo	26*	5244 [†]			WLR R2 (logOR CR vs. logHR OS)	R2=0.05, p=0.24	Slope 0.09	NR	Low	NE
Hackshaw 2005 ³⁶	CR	OS	Breast	- 1st - Recruited 1990 or after	Chemo	15*	3919 [†]			WLR R2 (logOR CR vs. logHR OS)	R2=0.36, p=0.01	Slope 0.16	NR	Low	NE
Foster 2011 ³⁴	CR	OS	Lung (SCLC)	1st	Chemo	3 (32 centres)	596 [†]	Spearman (logOR CR vs. logHR OS)	rs=0.50, p=NR	WLSR R2 (logOR CR vs. logHR OS)	R2=0.48, p=NR		NR	Low	NE
Lee 2011 ⁴⁸	CR	OS	NHL (aggressive)	1st	Chemo	36 [†]	16103 [†]	Spearman: a) diff CR vs. diff 3yr OS b) diff CR vs. diff 5yr OS	a) rs=0.58 (0.29 to 0.77), p=0.004 b) rs=0.50 (0.23 to 0.74), p=0.01				NR	Medium	NE
Lee 2011 ⁴⁸	CR	OS	NHL (indolent)	1st	Chemo	15 [†]	5128 [†]	Spearman: a) diff CR vs. diff 3yr OS b) diff CR vs. diff 5yr OS	a) rs=0.41 (-0.10 to 0.74), p=0.098 b) rs=0.21 (-0.34 to 0.50), p=0.44				NR	Medium	NE
Colloca & Venturino 2017 ²⁷	CR	OS	Ovarian	1st	Chemo	12	NR	Spearman (diff pCR vs. diff med OS)	rs=0.42, p=0.180				NR	Low	NE
DoR vs. OS															
Colloca 2016b ²⁹	DoR	OS	Colorectal	1st	Bevacizumab + chemo	5	NR	Spearman (diff med DoR vs. diff med OS)	rs=0.70, p=0.188				NR	Medium	NE
Colloca 2016a ²⁸	DoR	OS	Pancreatic	1st	Gemcitabine + chemo or targeted	7 [†]	NR	Spearman (diff med DoR vs. diff med OS)	rs=0.76, p=0.049				NR	Medium	NE
Colloca 2016a ²⁸	DoR	OS	Pancreatic	1st	Gemcitabine + chemo	3 [†]	NR	Spearman (diff med DoR vs. diff med OS)	rs=0.50, p=0.667				NR	Low	NE

Ref	SO	FO	Cancer	Line Sub-groups	Treatment	N stds	N pts	Treatment effect correlation methods	Correlation coefficient (95% CI), p-value	Treatment effect regression methods	Regression R2 (95% CI), p-value	Linear regression equation	STE	IQWiG	BSES2
Colloca 2016a ²⁸	DoR	OS	Pancreatic	1st	Gemcitabine + targeted	4 [†]	NR	Spearman (diff med DoR vs. diff med OS)	rs=0.40, p=0.600				NR	Low	NE

*Calculated from reported data. [†]Unclear for individual subgroups.

adj, adjusted; BSES2, Biomarker-Surrogate Evaluation Schema criteria 2; chemo, chemotherapy; CI, confidence interval; CR, complete response; diff, difference;; DoR, duration of response; FO, final outcome; HR, hazard ratio; IQWiG, Institute of Quality and Efficiency in Health Care; ln, natural logarithm; log, logarithm; LR, linear regression; med, median; mo, months; NE, not estimable; NHL, non-Hodgkin's lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; OR, odds ratio; ORR, overall response rate (ORR=PR+CR); OS, overall survival; PFS, progression-free survival; r, Pearson correlation; R2, regression coefficient of determination; rs, Spearman rank correlation; rr, relative risk; SCLC, small cell lung cancer; SO, surrogate outcome; STE, surrogate threshold effect; unwtcd, unweighted; wtd, weighted; WLR, weighted linear regression; WLSR, weighted least squares regression.

13 **Supplementary Table 9: Influence of clinical and study factors on association between ORR and OS**

Disease and factor comparison	Absolute association (r)		Treatment effect association (R ²)	
	Range Factor A	Range Factor B	Range Factor A	Range Factor B
AML				
Treatment line: (A) 1st line vs (B) subsequent line	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Treatment type: (A) targeted vs (B) systemic	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Response criteria: (A) RECIST vs (B) WHO	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
OS adjustment: (A) adjusted vs (B) unadjusted	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Data type: (A) Aggregate vs (B) IPD	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Biliary tract				
Treatment line: (A) 1st line vs (B) subsequent line	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Treatment type: (A) targeted vs (B) systemic	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	0.43 ⁵⁶	0.29 to 0.39 ⁵⁶
Response criteria: (A) RECIST vs (B) WHO	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
OS adjustment: (A) adjusted vs (B) unadjusted	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Data type: (A) Aggregate vs (B) IPD	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Breast				
Treatment line: (A) 1st line vs (B) subsequent line	0.61 ⁶⁴	-0.10 to 1.00 ⁵¹	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Treatment type: (A) targeted vs (B) systemic	0.61 ⁶⁴	-0.10 to 1.00 ⁵¹	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Response criteria: (A) RECIST vs (B) WHO	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
OS adjustment: (A) adjusted vs (B) unadjusted	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Data type: (A) Aggregate vs (B) IPD	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	0.26 to 0.41 ³⁶	0.10 to 0.20 ²³
Colorectal				
Treatment line: (A) 1st line vs (B) subsequent line	0.41 to 0.59 ^{52,75}	0.58 ³⁵	0.10 to 0.58 ^{25,29,46}	0.03 to 0.40 ³¹
Treatment type: (A) targeted vs (B) systemic	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	0.03 to 0.65 ^{29,31,73,77}	0.06 to 0.40 ^{25,26,46}
Response criteria: (A) RECIST vs (B) WHO	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	0.58 ²⁹	0.38 ²⁵
OS adjustment: (A) adjusted vs (B) unadjusted	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	0.4 ²⁶	0.03 to 0.65 ^{25,26,29,31,46,73,77}
Data type: (A) Aggregate vs (B) IPD	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	0.03 to 0.65 ^{26,29,31,46,73,77}	0.38 ²⁵
Gastric and gastroesophageal				
Treatment line: (A) 1st line vs (B) subsequent line	0.18 to 0.47 ⁴²	0.38 ⁷⁰	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>

Disease and factor comparison	Absolute association (r)		Treatment effect association (R ²)	
	Range Factor A	Range Factor B	Range Factor A	Range Factor B
Treatment type: (A) targeted vs (B) systemic	0.86 ⁶¹	0.18 to 0.47 ^{42,70}	INSUFFICIENT DATA	INSUFFICIENT DATA
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Glioblastoma				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Neuroendocrine				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
NSCLC				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	0.16 to 0.35 ^{46,58}	0.03 to 0.27 ³⁹
Treatment type: (A) targeted vs (B) systemic	-0.02 to 0.92 ^{45,49,50,65,71}	0.41 to 0.62 ^{68,71}	0.0007 to 0.84 ^{40,45,65,67,77}	0.16 to 0.44 ^{21,46,58}
Response criteria: (A) RECIST vs (B) WHO	0.52 ⁴⁹	0.62 ⁶⁸	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	0.03 to 0.27 ³⁹	0.0007 to 0.84 ^{21,22,39,40,45,46,58,65,67,77}
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Ovarian				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA

Disease and factor comparison	Absolute association (r)		Treatment effect association (R ²)	
	Range Factor A	Range Factor B	Range Factor A	Range Factor B
Data type: (A) Aggregate vs (B) IPD	0.82 ⁷²	0.56 ⁶⁶	INSUFFICIENT DATA	INSUFFICIENT DATA
Pancreatic / adenocarcinoma				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	0.28 ²⁸	0.01 to 0.30 ^{28,37,53}
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	0.01 to 0.04 ⁵³	0.07 to 0.30 ^{28,37,53}
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Prostate				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Renal / renal cell				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
SCLC				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Response criteria: (A) RECIST vs (B) WHO	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
OS adjustment: (A) adjusted vs (B) unadjusted	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Data type: (A) Aggregate vs (B) IPD	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Soft tissue sarcoma				
Treatment line: (A) 1st line vs (B) subsequent line	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA
Treatment type: (A) targeted vs (B) systemic	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA	INSUFFICIENT DATA

Disease and factor comparison	Absolute association (r)		Treatment effect association (R ²)	
	Range Factor A	Range Factor B	Range Factor A	Range Factor B
Response criteria: (A) RECIST vs (B) WHO	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
OS adjustment: (A) adjusted vs (B) unadjusted	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Data type: (A) Aggregate vs (B) IPD	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Unknown primary				
Treatment line: (A) 1st line vs (B) subsequent line	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Treatment type: (A) targeted vs (B) systemic	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Response criteria: (A) RECIST vs (B) WHO	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
OS adjustment: (A) adjusted vs (B) unadjusted	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Data type: (A) Aggregate vs (B) IPD	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Urothelial				
Treatment line: (A) 1st line vs (B) subsequent line	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Treatment type: (A) targeted vs (B) systemic	-0.12¹⁸	-0.02 to 0.78¹⁹	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Response criteria: (A) RECIST vs (B) WHO	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
OS adjustment: (A) adjusted vs (B) unadjusted	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
Data type: (A) Aggregate vs (B) IPD	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>	<i>INSUFFICIENT DATA</i>
AML, acute myeloid leukaemia; IPD, individual patient data; NSCLC, non-small cell lung cancer; r, correlation coefficient (e.g. Pearson or Spearman); R ² , regression coefficient of determination; SCLC, small cell lung cancer.				

15 **Supplementary Table 10: Regression equations for absolute (individual-level) associations**

Surrogate relationship	Cancer types and references	Surrogate	Final	Intercept	Slope
ORR to PFS	Colorectal ⁵²	ORR	Median PFS	3.20	0.10
	Lung (NSCLC) ⁷⁶	ORR	Median PFS	NR	0.07
	Ovarian ⁷²	ORR	Median PFS	2.59	0.12
	NHL ⁵⁴	log odds ORR	log median PFS	1.97	0.41
ORR to TTP	Gastric ⁴²	ORR	Median TTP	1.73	0.09
ORR to OS	Colorectal ⁵²	ORR	Median OS	10.45	0.09
	Lung (NSCLC) ⁷⁶	ORR	Median OS	NR	0.26
	Ovarian ⁷²	ORR	Median OS	9.48	0.28
	Gastric ⁴²	ORR	Median OS	5.89	0.08
CR to PFS	NHL ⁸¹	CR	Median PFS	0.83	0.46
	NHL ⁵⁴	log odds CR	log median PFS	2.38	0.34
CR, complete response; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTP, time to progression; VGPR, very good partial response.					

16

17

18 **Supplementary Table 11: Regression equations for treatment effect (trial-level) associations**

Surrogate relationship	Cancer types and refs	Subgroup	Based on difference in response				Based on relative risk or odds ratio for response			
			Surrogate	Final	Intercept	Slope	Surrogate	Final	Intercept	Slope
ORR to PFS	Lung (NSCLC) ⁷⁷		Diff ORR	HR PFS	NR	-0.02				
	Colorectal ⁷⁷		Diff ORR	HR PFS	NR	-0.04				
	Various ⁷⁷		Diff ORR	HR PFS	NR	-0.02				
	Colorectal ^{26,33}						logOR ORR	logHR PFS	-0.05	-0.32
	Breast ²⁴						logOR ORR	logHR PFS	0.10	0.50
	Various (immuno) ⁶⁷						logOR ORR	logHR PFS	-0.13	-0.24
ORR to OS	Colorectal ³¹	- All - Anti-angio - Non-anti-angio	Diff ORR	Diff median OS	NR	0.07 0.13 0.14				
	Colorectal ⁴⁶		Diff ORR	Diff median OS	0.34	0.10				
	Lung (NSCLC) ⁴⁶		Diff ORR	Diff median OS	-0.05	0.09				
	Colorectal ⁷⁷		Diff ORR	HR OS	NR	-0.03				
	Lung (NSCLC) ⁷⁷		Diff ORR	HR OS	NR	-0.01				
	Various ⁷⁷		Diff ORR	HR OS	NR	-0.02				
	Colorectal ^{26,33}	- All - No crossover					logOR ORR	logHR OS	-0.03 -0.04	-0.05 -0.10
	Breast ³⁶	- All - Recr. pre-1990 - Recr. 1990 or after					logOR ORR	logHR OS	-0.01 NR NR	0.28 0.28 0.24
	Lung (NSCLC) ⁵⁸						lnOR ORR	lnHR OS	-0.02	-0.13
	Various (immuno) ⁶⁷						logOR ORR	logHR OS	-0.13	-0.26
	Colorectal ³¹	- All - Anti-angio - Non-anti-angio					rr ORR	HR OS	NR	-0.03 -0.11 -0.06
	Renal cell ³²						ln rr ORR	-lnHR OS	-0.11	0.30
	Biliary tract ⁵⁶	- Chemo - Gemcitabine - Targeted					Ratio of ORR	log ratio of median OS	0.01 0.02 0.12	0.28 0.27 0.16

Surrogate relationship	Cancer types and refs	Subgroup	Based on difference in response				Based on relative risk or odds ratio for response			
			Surrogate	Final	Intercept	Slope	Surrogate	Final	Intercept	Slope
	Lung (SCLC) ⁴¹	- All - Pub. 1990-1996 - Pub. 1997-2008					rr ORR	Diff median OS	0.00 0.00 0.00	0.06 0.04 0.09
CR to PFS	NHL ⁶⁹						logOR CR 30mo	logHR PFS	-0.09	-0.64
	NHL ⁶⁹						logOR CR 24mo	logHR PFS	0.04	-0.73
CR to OS	Breast ³⁶	- All - Recr. pre-1990 - Recr. 1990 or after					logOR CR	logHR OS	-0.01 NR NR	0.13 0.09 0.16
Anti-angio, anti-angiogenic; CR, complete response; diff, difference; HR, hazard ratio; ln, natural logarithm; log, logarithm; NHL, non-Hodgkin's lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; OR, odds ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; pub, published; recr, recruited; rr, relative risk; SCLC, small cell lung cancer.										


20 **Supplementary Table 12: Surrogate threshold effect (STE) data reported per study**

Surrogate relationship	Cancer types and refs	Based on difference in response			Based on odds ratio for response		
		Surrogate	Final	STE	Surrogate	Final	STE
ORR to PFS	Various ⁷⁷	Diff ORR	HR PFS	15%			
ORR to OS	Colorectal ²⁶				OR ORR	OR OS	0.28
	NSCLC ³⁹	Diff ORR	HR OS	55%			
		Diff ORR	Diff median OS	41%			
	Various ⁷⁷	Diff ORR	HR OS	21%			
CR to PFS	NHL ⁶⁹				OR CR 30mo	HR PFS	1.56

CR, complete response; diff, difference; HR, hazard ratio; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; OR, odds ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; STE, surrogate threshold effect.

21


22 **Supplementary Figure 1: IQWiG scores for strength of association across all 202 analyses (within 63 included studies)**



23

24

25 **Supplementary Figure 2: BSES2 scores for strength of association across all 202 analyses (within 63 included studies)**



26

27

28

29